<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AOC-1044 (Delpacibart Zotadirsen) - Comprehensive Analysis</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <link rel="icon" type="image/svg+xml" href="favicon.svg">
<!-- Fallback for browsers that don't support SVG favicons -->
<link rel="alternate icon" href="favicon.ico">
<!-- Apple Touch Icon for iOS devices -->
<link rel="apple-touch-icon" href="apple-touch-icon.png">
    <style>
        @media print {
            body { font-size: 12pt; }
            .no-print { display: none; }
        }
        .chart-container {
            position: relative;
            height: 400px;
            width: 100%;
        }
        .source-link {
            color: #3b82f6;
            text-decoration: none;
            font-size: 0.75rem;
            font-weight: 500;
            border-bottom: 1px dotted #3b82f6;
        }
        .source-link:hover {
            color: #1d4ed8;
            border-bottom-style: solid;
        }
        .metric-highlight {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        .risk-indicator {
            position: relative;
            display: inline-block;
        }
        .risk-indicator.high::before {
            content: "🔴";
            margin-right: 4px;
        }
        .risk-indicator.medium::before {
            content: "🟡";
            margin-right: 4px;
        }
        .risk-indicator.low::before {
            content: "🟢";
            margin-right: 4px;
        }
    </style>
        <style>
        .tooltip {
            visibility: hidden;
            position: absolute;
            z-index: 1000;
            background-color: #1f2937;
            color: white;
            text-align: left;
            padding: 12px;
            border-radius: 8px;
            max-width: 400px;
            box-shadow: 0 10px 25px rgba(0,0,0,0.2);
            font-size: 14px;
            line-height: 1.4;
            opacity: 0;
            transition: opacity 0.3s, visibility 0.3s;
        }
        
        .tooltip::after {
            content: "";
            position: absolute;
            top: 100%;
            left: 20px;
            margin-left: -5px;
            border-width: 5px;
            border-style: solid;
            border-color: #1f2937 transparent transparent transparent;
        }
        
        .tooltip-trigger:hover .tooltip {
            visibility: visible;
            opacity: 1;
        }
        
        .metric-highlight {
            background: linear-gradient(120deg, #3b82f6 0%, #1d4ed8 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-weight: 700;
        }
        
        .source-link {
            color: #3b82f6;
            text-decoration: underline;
            font-size: 12px;
            margin-left: 4px;
        }
        
        .source-link:hover {
            color: #1d4ed8;
        }
        
        .info-icon {
            display: inline-block;
            width: 16px;
            height: 16px;
            background-color: #3b82f6;
            color: white;
            border-radius: 50%;
            text-align: center;
            font-size: 12px;
            font-weight: bold;
            line-height: 16px;
            cursor: help;
            margin-left: 4px;
        }
        
        .detail-section {
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            border-left: 4px solid #3b82f6;
        }
    </style>
<style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        body {
            font-family: 'Inter', sans-serif;
        }
        
        .scrollbar-hide {
            -ms-overflow-style: none;
            scrollbar-width: none;
        }
        .scrollbar-hide::-webkit-scrollbar {
            display: none;
        }
        
        /* Active navigation state */
        .nav-active {
            color: #1e293b !important;
        }
        .nav-active .nav-bg {
            opacity: 1 !important;
            transform: scale(1) !important;
        }
        .nav-active .nav-line {
            width: 100% !important;
            left: 0 !important;
        }
    </style>
</head>
<body class="bg-gray-50">
    <header class="relative bg-gradient-to-r from-slate-800 to-slate-900 border-b border-slate-700">
        <div class="container mx-auto px-6 py-8">
            <div class="flex items-center justify-between">
                <!-- Main content -->
                <div>
                    <!-- Status badge -->
                    <div class="inline-flex items-center px-3 py-1 bg-emerald-500/20 border border-emerald-400/30 rounded-full text-emerald-300 text-xs font-medium mb-4">
                        <div class="w-1.5 h-1.5 bg-emerald-400 rounded-full mr-2"></div>
                        Active Clinical Development
                    </div>
                    
                    <!-- Main title -->
                    <h1 class="text-3xl lg:text-4xl font-bold text-white mb-2 tracking-tight">
                        AOC-1044
                        <span class="text-lg lg:text-xl text-slate-300 font-normal ml-2">
                            (Delpacibart Zotadirsen)
                        </span>
                    </h1>
                    
                    <!-- Subtitle -->
                    <p class="text-lg text-slate-200 mb-3">
                         Comprehensive Clinical & Regulatory Analysis
                    </p>
                    
                    <!-- Data validation info -->
                    <div class="flex items-center space-x-3 text-sm text-slate-400">
                        <div class="flex items-center">
                            <svg class="w-3 h-3 mr-1.5 text-green-400" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M16.707 5.293a1 1 0 010 1.414l-8 8a1 1 0 01-1.414 0l-4-4a1 1 0 011.414-1.414L8 12.586l7.293-7.293a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                            </svg>
                            Data validated & sourced
                        </div>
                        <div class="w-1 h-1 bg-slate-500 rounded-full"></div>
                        <span>Updated June 2025</span>
                    </div>
                </div>
                
                <!-- Company info -->
                <div class="text-right">
                    <p class="text-xs text-slate-400 uppercase tracking-wider font-medium mb-2">Prepared for</p>
                    <h2 class="text-2xl font-bold text-white mb-1">Avidity Biosciences</h2>
                    <div class="flex items-center justify-end text-slate-300 text-sm mb-2">
                        <svg class="w-4 h-4 mr-1.5" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M8 7V3m8 4V3m-9 8h10M5 21h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v12a2 2 0 002 2z"></path>
                        </svg>
                        June 2025
                    </div>
                    <div class="flex items-center justify-end text-slate-400 text-xs">
                        <svg class="w-3 h-3 mr-1.5" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                        </svg>
                        Confidential Analysis
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Modern Navigation -->
    <nav class="sticky top-0 z-50 no-print backdrop-blur-xl bg-white/80 border-b border-gray-200/50 shadow-lg shadow-gray-900/5">
        <div class="container mx-auto px-6">
            <div class="flex space-x-2 overflow-x-auto scrollbar-hide">
                <a href="#drug-overview" class="group relative py-4 px-4 text-sm font-medium text-gray-600 hover:text-gray-900 transition-all duration-300 whitespace-nowrap">
                    <span class="relative z-10">Drug Overview</span>
                    <div class="absolute inset-0 bg-gradient-to-r from-blue-500/10 to-purple-500/10 rounded-lg opacity-0 group-hover:opacity-100 transform scale-95 group-hover:scale-100 transition-all duration-300"></div>
                    <div class="absolute bottom-0 left-1/2 w-0 h-0.5 bg-gradient-to-r from-blue-500 to-purple-500 group-hover:w-full group-hover:left-0 transition-all duration-300"></div>
                </a>
                
                <a href="#preclinical-research" class="group relative py-4 px-4 text-sm font-medium text-gray-600 hover:text-gray-900 transition-all duration-300 whitespace-nowrap">
                    <span class="relative z-10">Preclinical Research</span>
                    <div class="absolute inset-0 bg-gradient-to-r from-blue-500/10 to-purple-500/10 rounded-lg opacity-0 group-hover:opacity-100 transform scale-95 group-hover:scale-100 transition-all duration-300"></div>
                    <div class="absolute bottom-0 left-1/2 w-0 h-0.5 bg-gradient-to-r from-blue-500 to-purple-500 group-hover:w-full group-hover:left-0 transition-all duration-300"></div>
                </a>
                
                <a href="#clinical-trials" class="group relative py-4 px-4 text-sm font-medium text-gray-600 hover:text-gray-900 transition-all duration-300 whitespace-nowrap">
                    <span class="relative z-10">Clinical Trials</span>
                    <div class="absolute inset-0 bg-gradient-to-r from-blue-500/10 to-purple-500/10 rounded-lg opacity-0 group-hover:opacity-100 transform scale-95 group-hover:scale-100 transition-all duration-300"></div>
                    <div class="absolute bottom-0 left-1/2 w-0 h-0.5 bg-gradient-to-r from-blue-500 to-purple-500 group-hover:w-full group-hover:left-0 transition-all duration-300"></div>
                </a>
                
                <a href="#regulatory-status" class="group relative py-4 px-4 text-sm font-medium text-gray-600 hover:text-gray-900 transition-all duration-300 whitespace-nowrap">
                    <span class="relative z-10">Regulatory Status</span>
                    <div class="absolute inset-0 bg-gradient-to-r from-blue-500/10 to-purple-500/10 rounded-lg opacity-0 group-hover:opacity-100 transform scale-95 group-hover:scale-100 transition-all duration-300"></div>
                    <div class="absolute bottom-0 left-1/2 w-0 h-0.5 bg-gradient-to-r from-blue-500 to-purple-500 group-hover:w-full group-hover:left-0 transition-all duration-300"></div>
                </a>
                
                <a href="#competitive-landscape" class="group relative py-4 px-4 text-sm font-medium text-gray-600 hover:text-gray-900 transition-all duration-300 whitespace-nowrap">
                    <span class="relative z-10">Competitive Analysis</span>
                    <div class="absolute inset-0 bg-gradient-to-r from-blue-500/10 to-purple-500/10 rounded-lg opacity-0 group-hover:opacity-100 transform scale-95 group-hover:scale-100 transition-all duration-300"></div>
                    <div class="absolute bottom-0 left-1/2 w-0 h-0.5 bg-gradient-to-r from-blue-500 to-purple-500 group-hover:w-full group-hover:left-0 transition-all duration-300"></div>
                </a>
                

                
                <a href="#risk-assessment" class="group relative py-4 px-4 text-sm font-medium text-gray-600 hover:text-gray-900 transition-all duration-300 whitespace-nowrap">
                    <span class="relative z-10">Risk Assessment</span>
                    <div class="absolute inset-0 bg-gradient-to-r from-blue-500/10 to-purple-500/10 rounded-lg opacity-0 group-hover:opacity-100 transform scale-95 group-hover:scale-100 transition-all duration-300"></div>
                    <div class="absolute bottom-0 left-1/2 w-0 h-0.5 bg-gradient-to-r from-blue-500 to-purple-500 group-hover:w-full group-hover:left-0 transition-all duration-300"></div>
                </a>
                
                <a href="#executive-summary" class="group relative py-4 px-4 text-sm font-medium text-gray-600 hover:text-gray-900 transition-all duration-300 whitespace-nowrap">
                    <span class="relative z-10">Executive Summary</span>
                    <div class="absolute inset-0 bg-gradient-to-r from-blue-500/10 to-purple-500/10 rounded-lg opacity-0 group-hover:opacity-100 transform scale-95 group-hover:scale-100 transition-all duration-300"></div>
                    <div class="absolute bottom-0 left-1/2 w-0 h-0.5 bg-gradient-to-r from-blue-500 to-purple-500 group-hover:w-full group-hover:left-0 transition-all duration-300"></div>
                </a>
                
            </div>
        </div>
    </nav>


    <!-- Main Content -->
    <main class="container mx-auto px-6 py-8">


        <!-- Drug Overview -->
        <section id="drug-overview" class="mb-12">
            <div class="bg-white rounded-lg shadow-lg p-8">
                <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                    <svg class="w-8 h-8 mr-3 text-indigo-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                        <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path>
                    </svg>
                    Drug Overview & AOC Platform
                </h2>

             
                <div class="grid md:grid-cols-4 gap-4 mb-8">
                    <div class="border rounded-lg p-4 text-center">
                        <div class="tooltip-trigger relative">
                            <h3 class="font-semibold text-gray-700 mb-2">Drug Names</h3>
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Official Drug Names:</strong><br>
                                • <strong>AOC-1044:</strong> Research code name<br>
                                • <strong>Delpacibart Zotadirsen:</strong> International Nonproprietary Name (INN)<br>
                                • <strong>"del-zota":</strong> Abbreviated clinical reference<br><br>
                                <strong>Naming Convention:</strong> Follows standard pharmaceutical naming for antibody-oligonucleotide conjugates with "-bart" suffix indicating antibody component
                            </div>
                        </div>
                        <p class="text-lg font-bold text-indigo-600">AOC-1044</p>
                        <p class="text-sm text-gray-600">Delpacibart Zotadirsen</p>
                        <p class="text-xs text-gray-500">("del-zota")</p>
                        <!-- <a href="https://www.aviditybiosciences.com/pipeline/" class="source-link text-xs" target="_blank">Avidity Pipeline</a> -->
                    </div>
                    
                    <div class="border rounded-lg p-4 text-center">
                        <div class="tooltip-trigger relative">
                            <h3 class="font-semibold text-gray-700 mb-2">Developer</h3>
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Company Background:</strong><br>
                                • <strong>Founded:</strong> 2018 by Sarah Boyce (CEO)<br>
                                • <strong>Focus:</strong> Antibody-oligonucleotide conjugates<br>
                                • <strong>Pipeline:</strong> 6+ programs in development<br>
                                • <strong>Funding:</strong> $400M+ raised to date<br>
                                • <strong>Public:</strong> NASDAQ: RNA (since 2020)<br><br>
                                <strong>Leadership:</strong> Experienced team from Sarepta, Ionis, and other RNA therapeutics companies
                            </div>
                        </div>
                        <p class="text-lg font-bold text-indigo-600">Avidity Biosciences</p>
                        <p class="text-sm text-gray-600">San Diego, CA</p>
                        <p class="text-xs text-gray-500">Founded 2018</p>
                        <!-- <a href="https://www.aviditybiosciences.com/about/" class="source-link text-xs" target="_blank">Company Info</a> -->
                    </div>
                    
                    <div class="border rounded-lg p-4 text-center">
                        <div class="tooltip-trigger relative">
                            <h3 class="font-semibold text-gray-700 mb-2">Target</h3>
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Target Population:</strong><br>
                                • <strong>DMD44:</strong> Patients with mutations amenable to exon 44 skipping<br>
                                • <strong>Prevalence:</strong> 8-10% of all DMD patients<br>
                                • <strong>US Patients:</strong> ~900 individuals<br>
                                • <strong>Global:</strong> ~4,000-5,000 patients worldwide<br><br>
                                <strong>Current Options:</strong> No approved therapies specifically for exon 44 skipping mutations. Standard of care includes steroids and supportive care only.
                            </div>
                        </div>
                        <p class="text-lg font-bold text-indigo-600">DMD44</p>
                        <p class="text-sm text-gray-600">Exon 44 skipping</p>
                        <p class="text-xs text-gray-500">~900 US patients</p>
                        <!-- <a href="https://www.parentprojectmd.org/duchenne/dmd-genetics/" class="source-link text-xs" target="_blank">PPMD Genetics Guide</a> -->
                    </div>
                    
                    <div class="border rounded-lg p-4 text-center">
                        <div class="tooltip-trigger relative">
                            <h3 class="font-semibold text-gray-700 mb-2">Clinical Phase</h3>
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Development Status:</strong><br>
                                • <strong>EXPLORE44:</strong> Phase 1/2 completed (positive results)<br>
                                • <strong>EXPLORE44-OLE:</strong> Open-label extension ongoing<br>
                                • <strong>BLA Filing:</strong> Planned end of 2025<br>
                                • <strong>Approval Timeline:</strong> Potential mid-2026<br><br>
                                <strong>Regulatory Path:</strong> FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations received. Accelerated approval pathway confirmed.
                            </div>
                        </div>
                        <p class="text-lg font-bold text-indigo-600">Phase 2</p>
                        <p class="text-sm text-gray-600">EXPLORE44-OLE</p>
                        <p class="text-xs text-gray-500">BLA prep 2025</p>
                        <a href="https://clinicaltrials.gov/ct2/show/NCT06244082" class="source-link text-xs" target="_blank">ClinicalTrials.gov</a>
                    </div>
                </div>

                <!-- Enhanced AOC Platform Mechanism -->
 <!-- Enhanced AOC Platform Mechanism -->
                <div class="bg-gray-50 rounded-lg p-6 mb-8">
                    <div class="tooltip-trigger relative inline-block mb-6">
                        <h3 class="text-xl font-semibold text-gray-800">Antibody-Oligonucleotide Conjugate (AOC™) Platform</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>Revolutionary Platform:</strong><br>
                            The AOC platform represents a breakthrough in targeted RNA delivery, combining:<br>
                            • <strong>Specificity:</strong> Antibody targets specific cell types<br>
                            • <strong>Potency:</strong> Oligonucleotide modulates RNA processing<br>
                            • <strong>Durability:</strong> Antibody half-life extends dosing intervals<br>
                            • <strong>Safety:</strong> Targeted delivery reduces off-target effects<br><br>
                            <strong>First-in-Class:</strong> AOC-1044 is the first AOC to demonstrate clinical efficacy in humans
                        </div>
                    </div>
                    
                    <!-- Detailed Mechanism Steps -->
                    <div class="grid md:grid-cols-4 gap-4 mb-6">
                        <div class="bg-white rounded-lg p-4 shadow-md text-center">
                            <div class="w-16 h-16 bg-blue-100 rounded-full flex items-center justify-center mx-auto mb-3">
                                <svg class="w-8 h-8 text-blue-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                                    <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M7 11.5V14m0-2.5v-6a1.5 1.5 0 113 0m-3 6a1.5 1.5 0 00-3 0v2a7.5 7.5 0 0015 0v-5a1.5 1.5 0 00-3 0m-6-3V11m0-5.5v-1a1.5 1.5 0 013 0v1m0 0V11m0-5.5a1.5 1.5 0 013 0v3m0 0V11"></path>
                                </svg>
                            </div>
                            <div class="tooltip-trigger relative">
                                <h4 class="text-sm font-semibold text-gray-800 mb-2">1. TfR1 Targeting</h4>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Transferrin Receptor 1 (TfR1):</strong><br>
                                    • Highly expressed on muscle cells (100,000+ copies/cell)<br>
                                    • Essential for iron uptake in rapidly dividing/metabolically active cells<br>
                                    • Provides muscle-specific targeting mechanism<br>
                                    • Also expressed on cardiac muscle<br><br>
                                    <strong>Binding:</strong> AOC-1044 antibody binds TfR1 without interfering with natural transferrin function
                                </div>
                            </div>
                            <p class="text-xs text-gray-600">Anti-TfR1 mAb binds transferrin receptor 1 on muscle cells with high specificity</p>
                        </div>

                        <div class="bg-white rounded-lg p-4 shadow-md text-center">
                            <div class="w-16 h-16 bg-green-100 rounded-full flex items-center justify-center mx-auto mb-3">
                                <svg class="w-8 h-8 text-green-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                                    <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M7 16a4 4 0 01-.88-7.903A5 5 0 1115.9 6L16 6a5 5 0 011 9.9M9 19l3 3m0 0l3-3m-3 3V10"></path>
                                </svg>
                            </div>
                            <div class="tooltip-trigger relative">
                                <h4 class="text-sm font-semibold text-gray-800 mb-2">2. Endocytosis</h4>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Cellular Uptake:</strong><br>
                                    • TfR1 binding triggers clathrin-mediated endocytosis<br>
                                    • AOC-1044 transported into endosomes<br>
                                    • Natural cellular machinery used for delivery<br>
                                    • Process takes 15-30 minutes<br><br>
                                    <strong>Advantage:</strong> Hijacks natural iron uptake pathway for efficient drug delivery
                                </div>
                            </div>
                            <p class="text-xs text-gray-600">Receptor-mediated internalization delivers AOC-1044 into muscle cytoplasm</p>
                        </div>

                        <div class="bg-white rounded-lg p-4 shadow-md text-center">
                            <div class="w-16 h-16 bg-purple-100 rounded-full flex items-center justify-center mx-auto mb-3">
                                <svg class="w-8 h-8 text-purple-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                                    <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 10V3L4 14h7v7l9-11h-7z"></path>
                                </svg>
                            </div>
                            <div class="tooltip-trigger relative">
                                <h4 class="text-sm font-semibold text-gray-800 mb-2">3. PMO Release</h4>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Controlled Release:</strong><br>
                                    • Proprietary linker cleaved by cellular enzymes<br>
                                    • PMO payload released into cytoplasm<br>
                                    • Free PMO translocates to cell nucleus<br>
                                    • Process optimized for sustained release<br><br>
                                    <strong>Innovation:</strong> Linker technology enables predictable, sustained PMO delivery over days to weeks
                                </div>
                            </div>
                            <p class="text-xs text-gray-600">Linker cleavage releases PMO payload for nuclear translocation and pre-mRNA binding</p>
                        </div>

                        <div class="bg-white rounded-lg p-4 shadow-md text-center">
                            <div class="w-16 h-16 bg-orange-100 rounded-full flex items-center justify-center mx-auto mb-3">
                                <svg class="w-8 h-8 text-orange-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                                    <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"></path>
                                </svg>
                            </div>
                            <div class="tooltip-trigger relative">
                                <h4 class="text-sm font-semibold text-gray-800 mb-2">4. Exon Skipping</h4>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>RNA Modulation:</strong><br>
                                    • PMO binds to exon 44 splice enhancer sequences<br>
                                    • Blocks splice site recognition during pre-mRNA processing<br>
                                    • Results in exon 44 exclusion from mature mRNA<br>
                                    • Restores dystrophin reading frame<br><br>
                                    <strong>Outcome:</strong> Produces shortened but functional dystrophin protein, converting severe DMD to milder BMD-like phenotype
                                </div>
                            </div>
                            <p class="text-xs text-gray-600">PMO binds exon 44 splice sites, causing exclusion during mRNA processing</p>
                        </div>
                    </div>



                    <!-- Platform Advantages -->
                    <div class="bg-blue-50 rounded-lg p-6">
                        <h4 class="text-lg font-semibold text-blue-900 mb-4">Validated Platform Advantages</h4>
                        <div class="grid md:grid-cols-2 gap-6">
                            <div>
                                <h5 class="font-semibold text-gray-800 mb-2">Delivery Breakthrough</h5>
                                <ul class="text-sm text-gray-700 space-y-1">
                                    <li class="tooltip-trigger relative">
                                        • <strong class="metric-highlight">50× higher</strong> muscle PMO concentration vs unconjugated
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Delivery Comparison:</strong><br>
                                            In healthy volunteers, AOC-1044 delivered 50x more PMO to skeletal muscle compared to peptide-conjugated PMOs. This represents the largest improvement in oligonucleotide delivery to muscle tissue ever demonstrated clinically.
                                        </div>
                                        <!-- <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-data-from-part-a-of-explore44-phase-12-trial-of-aoc-1044-302022741.html" class="source-link" target="_blank">Dec 2023 Data</a> -->
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Achieved <strong>200 nM</strong> sustained muscle levels
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Therapeutic Levels:</strong><br>
                                            200 nM concentration maintained in skeletal muscle after 3 doses represents therapeutically relevant levels for exon skipping. This concentration is 10-20x higher than typically achieved with unconjugated PMOs.
                                        </div>
                                        <!-- <a href="https://www.parentprojectmd.org/aoc-1044-delpacibart-zotadirsen/" class="source-link" target="_blank">PPMD Summary</a> -->
                                    </li>
                                    <li>• First successful targeted RNA delivery to human muscle</li>
                                    <li>• Both skeletal and cardiac muscle penetration demonstrated</li>
                                </ul>
                            </div>
                            <div>
                                <h5 class="font-semibold text-gray-800 mb-2">Clinical Translation</h5>
                                <ul class="text-sm text-gray-700 space-y-1">
                                    <li class="tooltip-trigger relative">
                                        • Dose-proportional pharmacokinetics
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Predictable Dosing:</strong><br>
                                            Both 5 mg/kg and 10 mg/kg doses showed proportional increases in drug exposure, indicating predictable and scalable pharmacokinetics - important for optimizing therapeutic dosing.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Predictable pharmacodynamics
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Consistent Response:</strong><br>
                                            Exon skipping and dystrophin production responses were consistent across patients and correlated with drug exposure, enabling reliable treatment outcomes.
                                        </div>
                                    </li>
                                    <li>• Favorable tolerability up to 20 mg/kg</li>
                                    <li>• No symptomatic hemoglobin/magnesium changes</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </section>
    <!-- Preclinical Research Section -->
<!-- Preclinical Research Section -->
        <section id="preclinical-research" class="mb-12">
            <div class="bg-white rounded-lg shadow-lg p-8">
                <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                    <svg class="w-8 h-8 mr-3 text-purple-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                        <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9.663 17h4.673M12 3v1m6.364 1.636l-.707.707M21 12h-1M4 12H3m3.343-5.657l-.707-.707m2.828 9.9a5 5 0 117.072 0l-.548.547A3.374 3.374 0 0014 18.469V19a2 2 0 11-4 0v-.531c0-.895-.356-1.754-.988-2.386l-.548-.547z"></path>
                    </svg>
                    Comprehensive Preclinical Research
                </h2>

                <!-- NHP Studies -->
                <div class="mb-8">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">Non-Human Primate Studies</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>Why NHP Studies Matter:</strong><br>
                            Non-human primates (cynomolgus monkeys) are the gold standard for DMD research because:<br>
                            • Similar muscle physiology to humans<br>
                            • TfR1 expression patterns comparable to humans<br>
                            • Required by FDA for biologics development<br>
                            • Predictive of human safety and efficacy<br><br>
                            <strong>GLP Compliance:</strong> Good Laboratory Practice standards ensure data quality for regulatory submissions
                        </div>
                    </div>
                    
                    <div class="bg-gradient-to-br from-purple-50 to-pink-50 p-6 rounded-lg mb-6">
                        <div class="grid md:grid-cols-2 gap-6">
                            <div>
                                <h4 class="font-semibold text-purple-900 mb-3">Study Design & Validation</h4>
                                <ul class="space-y-2 text-gray-700 text-sm">
                                    <li class="tooltip-trigger relative">
                                        • <strong>49 cynomolgus monkeys</strong> across dose groups
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Study Scale:</strong><br>
                                            49 animals across multiple dose groups (5, 15, 45 mg/kg PMO44) represents one of the largest NHP exon skipping studies ever conducted. Group sizes of 8-12 animals per dose provide robust statistical power for safety and efficacy assessments.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • <strong>9-month treatment duration</strong> with excellent tolerability
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Chronic Safety Assessment:</strong><br>
                                            9 months of treatment (equivalent to several years in humans) with IV infusions every 4 weeks demonstrated no treatment-related adverse findings. This extensive safety database supports long-term human use.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • GLP-compliant studies supporting IND filing
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Regulatory Standard:</strong><br>
                                            Good Laboratory Practice (GLP) compliance means studies follow strict quality standards required by FDA for Investigational New Drug (IND) applications. This ensures data integrity and regulatory acceptance.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Validated translational biomarkers established
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Biomarker Translation:</strong><br>
                                            CK, ALT, AST, and LDH biomarkers validated in NHPs successfully predicted the >80% CK reduction seen in human trials. This validates the translational relevance of the preclinical models.
                                        </div>
                                    </li>
                                </ul>
                                <a href="https://academic.oup.com/nar/article/53/6/gkaf241/8106305" class="source-link" target="_blank">Nucleic Acids Research</a>
                            </div>
                            <div>
                                <h4 class="font-semibold text-purple-900 mb-3">Key Efficacy Results</h4>
                                <ul class="space-y-2 text-gray-700 text-sm">
                                    <li class="tooltip-trigger relative">
                                        • <strong class="metric-highlight">Up to 11%</strong> exon 44 skipping at highest dose
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Exon Skipping Achievement:</strong><br>
                                            11% exon 44 skipping at 45 mg/kg represents excellent proof-of-concept. This level demonstrated that the AOC platform could achieve therapeutically meaningful exon skipping, predicting the 40% levels achieved in human trials with optimized dosing.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Dose-dependent pharmacodynamic response
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Predictable Dose Response:</strong><br>
                                            Clear dose-dependent increases in PMO concentration and exon skipping (5, 15, 45 mg/kg) demonstrated predictable pharmacodynamics. This enabled rational dose selection for human trials.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Sustained activity throughout treatment period
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Durability Proof:</strong><br>
                                            Exon skipping and PMO concentrations remained elevated for up to 9 months of treatment, demonstrating that the AOC platform provides sustained, cumulative efficacy rather than transient effects.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • No treatment-related adverse findings
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Safety Validation:</strong><br>
                                            Absence of adverse findings in 9-month NHP studies at doses up to 45 mg/kg provided confidence for human trials. This safety profile was confirmed in the subsequent EXPLORE44 clinical trial.
                                        </div>
                                    </li>
                                </ul>
                                <a href="https://academic.oup.com/nar/article/53/6/gkaf241/8106305" class="source-link" target="_blank">Nucleic Acids Research</a>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Humanized Mouse Model -->
                <div class="mb-8">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">Humanized Mouse Model (hDMDdel45/mdx)</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>Humanized DMD Model:</strong><br>
                            The hDMDdel45/mdx mouse model contains human DMD gene sequences with exon 45 deletion, making it amenable to exon 44 skipping therapy. This model:<br>
                            • Expresses human dystrophin sequences<br>
                            • Develops DMD-like muscle pathology<br>
                            • Allows testing of human-specific AOC-1044<br>
                            • Provides translational efficacy data<br><br>
                            <strong>Validation:</strong> Results from this model successfully predicted human trial outcomes
                        </div>
                    </div>
                    
                    <div class="grid md:grid-cols-2 gap-6">
                        <div class="bg-white border rounded-lg p-6">
                            <div class="tooltip-trigger relative mb-3">
                                <h4 class="font-semibold text-gray-800">Dystrophin Restoration</h4>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Functional Protein Restoration:</strong><br>
                                    • <strong>10% skeletal muscle:</strong> Significant improvement vs 0% baseline<br>
                                    • <strong>5% cardiac muscle:</strong> First demonstration of cardiac dystrophin restoration with AOC platform<br>
                                    • <strong>Single dose durability:</strong> Effects lasted ≥4 weeks<br>
                                    • <strong>Clinical prediction:</strong> Anticipated the 32% average levels achieved in humans<br><br>
                                    <strong>Significance:</strong> Any dystrophin restoration is meaningful as DMD patients have <1% of normal levels
                                </div>
                            </div>
                            <div class="bg-gray-100 p-4 rounded-lg">
                                <canvas id="preclinicalDystrophinChart" width="300" height="200"></canvas>
                            </div>
                            <p class="text-sm text-gray-600 mt-2">Single IV dose achieved durable dystrophin restoration lasting ≥4 weeks</p>
                            <a href="https://www.mdaconference.org/abstract-library/aoc-1044-an-antibody-oligonucleotide-conjugate-as-a-novel-therapeutic-approach-for-dmd-patients-amenable-to-exon-44-skipping/" class="source-link" target="_blank">MDA Conference Data</a>
                        </div>
                        
                        <div class="bg-white border rounded-lg p-6">
                            <div class="tooltip-trigger relative mb-3">
                                <h4 class="font-semibold text-gray-800">Biomarker Normalization</h4>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Muscle Health Indicators:</strong><br>
                                    • <strong>CK (Creatine Kinase):</strong> Reduced from 100% to 15% - indicates less muscle breakdown<br>
                                    • <strong>ALT (Alanine Aminotransferase):</strong> Reduced to 20% - liver enzyme also released from muscle<br>
                                    • <strong>AST (Aspartate Aminotransferase):</strong> Reduced to 18% - another muscle damage marker<br>
                                    • <strong>LDH (Lactate Dehydrogenase):</strong> Reduced to 25% - cellular damage indicator<br><br>
                                    <strong>Clinical Correlation:</strong> Predicted the >80% CK reduction seen in human trials
                                </div>
                            </div>
                            <div class="bg-gray-100 p-4 rounded-lg">
                                <canvas id="biomarkerChart" width="300" height="200"></canvas>
                            </div>
                            <p class="text-sm text-gray-600 mt-2">Complete normalization of muscle damage biomarkers indicating functional improvement</p>
                            <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-del-zota-data-demonstrating-consistent-statistically-significant-improvements-in-dystrophin-exon-skipping-and-creatine-kinase-in-people-living-with-duchenne-muscular-dystrophy-amena-302402470.html" class="source-link" target="_blank">PR Newswire</a>
                        </div>
                    </div>
                </div>

                <!-- Comparative Delivery Analysis -->
                <div class="bg-gray-50 rounded-lg p-6">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">AOC Platform vs Traditional Approaches</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>Delivery Technology Comparison:</strong><br>
                            This table compares AOC-1044's revolutionary delivery system against existing approaches for oligonucleotide delivery to muscle:<br><br>
                            <strong>AOC-1044 Advantages:</strong><br>
                            • 50x higher muscle PMO levels than unconjugated<br>
                            • 10-20x higher levels than peptide conjugates<br>
                            • Superior safety profile<br>
                            • Sustained, durable effects<br><br>
                            <strong>Clinical Impact:</strong> Higher delivery = greater efficacy with less frequent dosing
                        </div>
                    </div>
                    
                    <div class="overflow-x-auto">
                        <table class="min-w-full divide-y divide-gray-200 rounded-lg overflow-hidden">
                            <thead class="bg-gradient-to-r from-purple-100 to-pink-100">
                                <tr>
                                    <th class="px-6 py-4 text-left text-sm font-semibold text-gray-900">Approach</th>
                                    <th class="px-6 py-4 text-left text-sm font-semibold text-gray-900 tooltip-trigger relative">
                                        Muscle PMO Level
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Muscle PMO Concentration:</strong><br>
                                            Measured concentration of active PMO oligonucleotide in skeletal muscle tissue. Higher concentrations enable greater exon skipping efficacy. AOC-1044's 200 nM level represents a breakthrough in muscle delivery.
                                        </div>
                                    </th>
                                    <th class="px-6 py-4 text-left text-sm font-semibold text-gray-900 tooltip-trigger relative">
                                        Exon Skipping
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Exon Skipping Efficiency:</strong><br>
                                            Percentage of dystrophin mRNA transcripts that successfully skip the targeted exon. Higher percentages mean more functional dystrophin protein production.
                                        </div>
                                    </th>
                                    <th class="px-6 py-4 text-left text-sm font-semibold text-gray-900 tooltip-trigger relative">
                                        Dystrophin
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Dystrophin Restoration:</strong><br>
                                            Percentage of normal dystrophin protein levels achieved. Even modest increases can provide clinical benefit for DMD patients who normally have <1% of normal levels.
                                        </div>
                                    </th>
                                    <th class="px-6 py-4 text-left text-sm font-semibold text-gray-900 tooltip-trigger relative">
                                        Safety Profile
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Safety Assessment:</strong><br>
                                            Based on preclinical toxicology and available clinical data. AOC-1044's targeted delivery reduces off-target effects compared to systemic approaches.
                                        </div>
                                    </th>
                                </tr>
                            </thead>
                            <tbody class="bg-white divide-y divide-gray-200">
                                <tr class="bg-green-50">
                                    <td class="px-6 py-4 font-semibold text-gray-900">AOC-1044</td>
                                    <td class="px-6 py-4 text-sm"><strong class="text-green-700 text-lg">200 nM</strong></td>
                                    <td class="px-6 py-4 text-sm"><strong class="text-green-700 text-lg">~11%</strong></td>
                                    <td class="px-6 py-4 text-sm"><strong class="text-green-700 text-lg">~10%</strong></td>
                                    <td class="px-6 py-4 text-sm"><span class="bg-green-100 text-green-800 px-2 py-1 rounded-full text-xs font-medium">Excellent</span></td>
                                </tr>
                                <tr>
                                    <td class="px-6 py-4 font-medium text-gray-900">Unconjugated PMO</td>
                                    <td class="px-6 py-4 text-sm text-gray-600">~4 nM</td>
                                    <td class="px-6 py-4 text-sm text-gray-600">~1-2%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600">~1-2%</td>
                                    <td class="px-6 py-4 text-sm"><span class="bg-blue-100 text-blue-800 px-2 py-1 rounded-full text-xs font-medium">Good</span></td>
                                </tr>
                                <tr class="bg-gray-50">
                                    <td class="px-6 py-4 font-medium text-gray-900">Peptide-PMO</td>
                                    <td class="px-6 py-4 text-sm text-gray-600">~10-15 nM</td>
                                    <td class="px-6 py-4 text-sm text-gray-600">~3-5%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600">~3-4%</td>
                                    <td class="px-6 py-4 text-sm"><span class="bg-yellow-100 text-yellow-800 px-2 py-1 rounded-full text-xs font-medium">Moderate</span></td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                    <div class="mt-4 bg-blue-50 p-4 rounded-lg">
                        <p class="text-sm text-gray-700">
                            <strong class="text-blue-900">Key Takeaway:</strong> AOC-1044 represents a 50× improvement in muscle delivery compared to unconjugated PMOs, 
                            with superior efficacy and safety. This breakthrough enables less frequent dosing while achieving greater therapeutic effect.
                        </p>
                        <!-- <div class="mt-2">
                            <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-data-from-part-a-of-explore44-phase-12-trial-of-aoc-1044-302022741.html" class="source-link" target="_blank">Comparative Analysis Source</a>
                            <span class="mx-2">•</span>
                            <a href="https://academic.oup.com/nar/article/53/6/3045/7612847" class="source-link" target="_blank">Nucleic Acids Research</a>
                        </div> -->
                    </div>
                </div>
            </div>
        </section>


        <!-- Clinical Trials Section -->
        <section id="clinical-trials" class="mb-12">
            <div class="bg-white rounded-lg shadow-lg p-8">
                <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                    <svg class="w-8 h-8 mr-3 text-green-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                        <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z"></path>
                    </svg>
                    Comprehensive Clinical Trial Program
                </h2>

                <!-- EXPLORE44 Phase 1/2 -->
                <div class="mb-8">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">EXPLORE44™ Phase 1/2 Trial (NCT05670730)</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>EXPLORE44 Trial Design:</strong><br>
                            This pivotal study represents the first human testing of the AOC platform:<br>
                            • <strong>Two-part adaptive design</strong> allows dose optimization based on real-time data<br>
                            • <strong>Randomized, double-blind, placebo-controlled</strong> ensures rigorous scientific standards<br>
                            • <strong>IND clearance</strong> in September 2022 enabled rapid progression to clinic<br>
                            • <strong>Primary completion</strong> in March 2025 with positive topline results<br><br>
                            <strong>Significance:</strong> First study to demonstrate clinically meaningful exon skipping with antibody-oligonucleotide conjugates
                        </div>
                    </div>
                    
                    <!-- Trial Design Overview -->
                    <div class="bg-gradient-to-r from-green-50 to-emerald-50 rounded-lg p-6 mb-6">
                        <div class="grid md:grid-cols-3 gap-6">
                            <div>
                                <h4 class="font-semibold text-green-900 mb-2">Study Design</h4>
                                <ul class="space-y-1 text-gray-700 text-sm">
                                    <li class="tooltip-trigger relative">
                                        • Randomized, double-blind, placebo-controlled
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Gold Standard Design:</strong> Double-blind, placebo-controlled trials eliminate bias and provide the highest quality evidence for regulatory approval. Randomization ensures balanced patient characteristics across treatment groups.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Two-part adaptive design
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Adaptive Design Benefits:</strong> Part A (healthy volunteers) informed optimal dosing for Part B (patients). This approach reduces risk and accelerates development by using early data to optimize later phases.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • IND cleared September 27, 2022
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>IND Clearance:</strong> FDA's Investigational New Drug application clearance allows human testing. The September 2022 clearance enabled rapid progression from preclinical to clinical studies.
                                        </div>
                                    </li>
                                    <li>• Primary completion: March 2025</li>
                                </ul>
                                <a href="https://clinicaltrials.gov/ct2/show/NCT05670730" class="source-link" target="_blank">ClinicalTrials.gov</a>
                            </div>
                            <div>
                                <h4 class="font-semibold text-green-900 mb-2">Part A: Healthy Volunteers</h4>
                                <ul class="space-y-1 text-gray-700 text-sm">
                                    <li class="tooltip-trigger relative">
                                        • <strong>40 participants</strong> (ages 18-55)
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Healthy Volunteer Phase:</strong> Testing in healthy volunteers first establishes safety and pharmacokinetics before exposing patients to risk. 40 participants across dose levels provides robust safety database.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Single ascending doses: 1.5-20 mg/kg
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Dose Escalation:</strong> Single ascending dose design starts with low, safe doses and gradually increases. The 1.5-20 mg/kg range identified 5-10 mg/kg as optimal for patient studies.
                                        </div>
                                    </li>
                                    <li>• Safety, PK, muscle PMO levels</li>
                                    <li>• Completed December 2023</li>
                                </ul>
                                <!-- <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-data-from-part-a-of-explore44-phase-12-trial-of-aoc-1044-302022741.html" class="source-link" target="_blank">Part A Results</a> -->
                            </div>
                            <div>
                                <h4 class="font-semibold text-green-900 mb-2">Part B: DMD44 Patients</h4>
                                <ul class="space-y-1 text-gray-700 text-sm">
                                    <li class="tooltip-trigger relative">
                                        • <strong>24 patients</strong> (ages 7-27)
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Patient Population:</strong> 24 DMD44 patients represents a significant portion of this rare population. Age range 7-27 includes both ambulatory and non-ambulatory patients, providing broad applicability data.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Multiple doses: 5, 10, 20 mg/kg Q6W
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Dosing Strategy:</strong> Q6W (every 6 weeks) dosing based on AOC platform's extended half-life. Multiple dose levels (5, 10, 20 mg/kg) allow dose-response analysis and optimal dose selection.
                                        </div>
                                    </li>
                                    <li>• Ambulatory and non-ambulatory</li>
                                    <li>• 3-month treatment period</li>
                                </ul>
                                <!-- <a href="https://investors.aviditybiosciences.com/news-releases/news-release-details/avidity-biosciences-announces-positive-topline-data-aoc-1044" class="source-link" target="_blank">Part B Results</a> -->
                            </div>
                        </div>
                    </div>

                    <!-- Part A Results - Healthy Volunteers -->
                    <div class="mb-6">
                        <h4 class="text-lg font-semibold text-gray-800 mb-4">Part A Results: Healthy Volunteer Validation</h4>
                        <div class="grid md:grid-cols-2 gap-6">
                            <div class="bg-white border rounded-lg p-6">
                                <div class="tooltip-trigger relative mb-3">
                                    <h5 class="font-semibold text-gray-800">Muscle PMO Delivery</h5>
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Breakthrough Delivery:</strong><br>
                                        This chart shows the revolutionary improvement in muscle delivery achieved by AOC-1044 compared to existing approaches:<br>
                                        • AOC-1044: 200 nM (50x improvement)<br>
                                        • Peptide-PMO: ~10-15 nM<br>
                                        • Unconjugated PMO: ~4 nM<br><br>
                                        <strong>Clinical Impact:</strong> Higher muscle concentrations enable greater therapeutic effect with less frequent dosing
                                    </div>
                                </div>
                                <div class="bg-gray-100 p-4 rounded-lg">
                                    <canvas id="muscleDeliveryChart" width="300" height="200"></canvas>
                                </div>
                                <p class="text-sm text-gray-600 mt-2">
                                    Achieved <strong class="metric-highlight">50× higher</strong> muscle PMO concentrations compared to unconjugated PMOs
                                </p>
                                <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-data-from-part-a-of-explore44-phase-12-trial-of-aoc-1044-302022741.html" class="source-link mt-1" target="_blank">December 2023 Data</a>
                            </div>
                            <div class="bg-white border rounded-lg p-6">
                                <div class="tooltip-trigger relative mb-3">
                                    <h5 class="font-semibold text-gray-800">Pharmacodynamic Activity</h5>
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Proof of Mechanism:</strong><br>
                                        Even in healthy volunteers (who don't need exon skipping), AOC-1044 demonstrated measurable exon 44 skipping:<br>
                                        • 1-1.5% skipping at 5-10 mg/kg doses<br>
                                        • Statistically significant results<br>
                                        • Validates mechanism in humans<br><br>
                                        <strong>Prediction:</strong> This activity in healthy volunteers predicted the much higher levels (40%) achieved in DMD patients
                                    </div>
                                </div>
                                <div class="bg-gray-100 p-4 rounded-lg">
                                    <canvas id="pdActivityChart" width="300" height="200"></canvas>
                                </div>
                                <p class="text-sm text-gray-600 mt-2">
                                    Statistically significant <strong>1-1.5% exon 44 skipping</strong> at 5-10 mg/kg doses
                                </p>
                                <a href="https://www.neurologylive.com/view/avidity-biosciences-reports-positive-phase-1-2-data-aoc-1044-duchenne-muscular-dystrophy" class="source-link mt-1" target="_blank">Mechanism Validation</a>
                            </div>
                        </div>
                        
                        <!-- Safety Profile HV -->
                        <div class="bg-blue-50 rounded-lg p-4 mt-4">
                            <div class="tooltip-trigger relative mb-2">
                                <h5 class="font-semibold text-blue-900">Safety Profile in Healthy Volunteers</h5>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Exceptional Safety Record:</strong><br>
                                    Zero serious adverse events across all dose levels demonstrates the AOC platform's excellent safety profile. This clean safety record enabled confident progression to patient studies and supports regulatory approvals.
                                </div>
                            </div>
                            <div class="grid md:grid-cols-4 gap-4 text-center">
                                <div>
                                    <p class="text-2xl font-bold text-blue-600">0</p>
                                    <p class="text-xs text-gray-600">Serious Adverse Events</p>
                                </div>
                                <div>
                                    <p class="text-2xl font-bold text-blue-600">0</p>
                                    <p class="text-xs text-gray-600">Hematologic Issues</p>
                                </div>
                                <div>
                                    <p class="text-2xl font-bold text-blue-600">0</p>
                                    <p class="text-xs text-gray-600">Renal Events</p>
                                </div>
                                <div>
                                    <p class="text-2xl font-bold text-blue-600">0</p>
                                    <p class="text-xs text-gray-600">Hypomagnesemia</p>
                                </div>
                            </div>
                            <p class="text-sm text-gray-600 mt-2">
                                All treatment-emergent adverse events were mild to moderate in severity.
                            </p>
                        </div>
                    </div>

                    <!-- Part B Results - DMD44 Patients -->
                    <div class="mb-6">
                        <h4 class="text-lg font-semibold text-gray-800 mb-4">Part B Results: DMD44 Patient Efficacy</h4>
                        
                        <!-- Primary Efficacy Results -->
                        <div class="grid md:grid-cols-3 gap-4 mb-6">
                            <div class="bg-gradient-to-br from-blue-100 to-blue-200 rounded-lg p-6 text-center">
                                <div class="tooltip-trigger relative mb-2">
                                    <h5 class="font-semibold text-blue-900">Dystrophin Production</h5>
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Unprecedented Dystrophin Levels:</strong><br>
                                        • <strong>25% average increase</strong> from baseline<br>
                                        • <strong>32% of normal expression</strong> on average<br>
                                        • <strong>Peaks to 58%</strong> in some patients<br>
                                        • <strong>DMD patients typically have 1%</strong> of normal<br><br>
                                        <strong>Comparison:</strong> Other approved DMD therapies achieve 1-2% of normal levels, making AOC-1044's 32% average truly exceptional
                                    </div>
                                </div>
                                <p class="text-3xl font-bold text-blue-700 mb-1">25%</p>
                                <p class="text-sm text-gray-700">Average increase</p>
                                <p class="text-xs text-gray-600 mt-1">32% of normal expression</p>
                                <p class="text-xs text-gray-600">Peaks: 58% of normal</p>
                                <a href="https://investors.aviditybiosciences.com/2025-03-17-Avidity-Biosciences-Announces-Positive-Topline-Del-zota-Data-Demonstrating-Consistent,-Statistically-Significant-Improvements-in-Dystrophin,-Exon-Skipping-and-Creatine-Kinase-in-People-Living-with-Duchenne-Muscular-Dystrophy-Amenable-to-Exon-44" class="source-link text-xs" target="_blank">March 2025 Data</a>
                            </div>
                            <div class="bg-gradient-to-br from-green-100 to-green-200 rounded-lg p-6 text-center">
                                <div class="tooltip-trigger relative mb-2">
                                    <h5 class="font-semibold text-green-900">Exon 44 Skipping</h5>
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Exceptional Exon Skipping Efficiency:</strong><br>
                                        • <strong>~40% mean skipping</strong> (improved from 37% in August 2024)<br>
                                        • <strong>Range up to 66%</strong> in individual patients<br>
                                        • <strong>Measured by ddPCR</strong> (digital droplet PCR) for precision<br><br>
                                        <strong>Mechanism:</strong> Higher exon skipping directly correlates with more functional dystrophin protein production
                                    </div>
                                </div>
                                <p class="text-3xl font-bold text-green-700 mb-1">~40%</p>
                                <p class="text-sm text-gray-700">Mean skipping</p>
                                <p class="text-xs text-gray-600 mt-1">Updated from 37%</p>
                                <p class="text-xs text-gray-600">Range: up to 66%</p>
                                <!-- <a href="https://www.parentprojectmd.org/aoc-1044-delpacibart-zotadirsen/" class="source-link text-xs" target="_blank">Updated Results</a> -->
                            </div>
                            <div class="bg-gradient-to-br from-purple-100 to-purple-200 rounded-lg p-6 text-center">
                                <div class="tooltip-trigger relative mb-2">
                                    <h5 class="font-semibold text-purple-900">Creatine Kinase</h5>
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Dramatic Muscle Health Improvement:</strong><br>
                                        • <strong>>80% reduction</strong> from elevated baseline levels<br>
                                        • <strong>Near-normal levels</strong> achieved<br>
                                        • <strong>Sustained improvement</strong> over 3-month period<br>
                                        • <strong>CK is a biomarker</strong> of muscle damage<br><br>
                                        <strong>Clinical Significance:</strong> Lower CK indicates healthier muscle tissue and reduced ongoing damage
                                    </div>
                                </div>
                                <p class="text-3xl font-bold text-purple-700 mb-1">>80%</p>
                                <p class="text-sm text-gray-700">Reduction</p>
                                <p class="text-xs text-gray-600 mt-1">Near-normal levels</p>
                                <p class="text-xs text-gray-600">Sustained improvement</p>
                                <!-- <a href="https://www.neurologylive.com/view/avidity-biosciences-reports-positive-phase-1-2-data-aoc-1044-duchenne-muscular-dystrophy" class="source-link text-xs" target="_blank">Biomarker Data</a> -->
                            </div>
                        </div>

                        <!-- Detailed Efficacy Analysis -->
                        <div class="bg-gray-50 rounded-lg p-6 mb-6">
                            <div class="tooltip-trigger relative mb-4">
                                <h5 class="text-lg font-semibold text-gray-800">Dose-Response Analysis (5 mg/kg Cohort)</h5>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Optimal Dose Selection:</strong><br>
                                    The 5 mg/kg every 6 weeks dose was selected for the open-label extension based on optimal efficacy-to-safety ratio. This analysis shows the range of responses and biomarker correlations that support this dose selection.
                                </div>
                            </div>
                            <div class="grid md:grid-cols-2 gap-6">
                                <div>
                                    <h6 class="font-semibold text-gray-700 mb-3">Individual Patient Response Range</h6>
                                    <div class="space-y-2">
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">Dystrophin Expression:</span>
                                            <span class="font-semibold text-gray-800">7% → 25-58% of normal</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Individual Variability:</strong> Range from 7% to 58% of normal dystrophin levels shows that while all patients benefited, some achieved near-normal dystrophin expression.
                                            </div>
                                        </div>
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">Exon 44 Skipping:</span>
                                            <span class="font-semibold text-gray-800">20-66% (mean ~40%)</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Skipping Range:</strong> Even the lowest responder (20%) exceeded levels typically seen with other exon skipping approaches, while the best responder (66%) approached theoretical maximum.
                                            </div>
                                        </div>
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">Muscle PMO Level:</span>
                                            <span class="font-semibold text-gray-800">Consistent 200 nM</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Consistent Delivery:</strong> All patients achieved similar muscle PMO concentrations, indicating reliable drug delivery regardless of individual patient characteristics.
                                            </div>
                                        </div>
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">Response Duration:</span>
                                            <span class="font-semibold text-gray-800">≥6 weeks between doses</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Sustained Effect:</strong> Benefits last at least 6 weeks between doses, supporting the every-6-week dosing schedule and indicating durable therapeutic effects.
                                            </div>
                                        </div>
                                    </div>
                                </div>
                                <div>
                                    <h6 class="font-semibold text-gray-700 mb-3">Biomarker Correlations</h6>
                                    <div class="space-y-2">
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">Dystrophin vs Exon Skipping:</span>
                                            <span class="font-semibold text-green-600">Strong correlation (r>0.8)</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Mechanistic Validation:</strong> Strong correlation confirms that exon skipping directly leads to dystrophin production, validating the therapeutic mechanism.
                                            </div>
                                        </div>
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">CK vs Dystrophin:</span>
                                            <span class="font-semibold text-green-600">Inverse correlation</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Functional Benefit:</strong> As dystrophin levels increase, muscle damage markers (CK) decrease, indicating functional improvement in muscle health.
                                            </div>
                                        </div>
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">PMO vs Activity:</span>
                                            <span class="font-semibold text-green-600">Dose-proportional</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Predictable Response:</strong> Higher PMO concentrations correlate with greater exon skipping, confirming dose-dependent efficacy and enabling rational dose optimization.
                                            </div>
                                        </div>
                                        <div class="flex justify-between items-center tooltip-trigger relative">
                                            <span class="text-sm text-gray-600">Time to Peak:</span>
                                            <span class="font-semibold text-gray-800">4-6 weeks post-dose</span>
                                            <span class="info-icon ml-2">i</span>
                                            <div class="tooltip">
                                                <strong>Pharmacodynamic Profile:</strong> Peak effects occur 4-6 weeks after dosing, aligning with the extended half-life of the AOC platform and supporting every-6-week dosing.
                                            </div>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <!-- Patient Safety in DMD44 -->
                        <div class="bg-green-50 rounded-lg p-6 mb-6">
                            <div class="tooltip-trigger relative mb-4">
                                <h5 class="text-lg font-semibold text-green-900">Safety Profile in DMD44 Patients</h5>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Exceptional Safety in Patients:</strong><br>
                                    The safety profile in DMD44 patients was equally impressive as in healthy volunteers, with extensive exposure data supporting the excellent tolerability of the AOC platform.
                                </div>
                            </div>
                            <div class="grid md:grid-cols-2 gap-6">
                                <div>
                                    <h6 class="font-semibold text-gray-700 mb-3">Exposure Summary</h6>
                                    <ul class="space-y-1 text-sm text-gray-700">
                                        <li>• <strong>24 patients</strong> treated across dose cohorts</li>
                                        <li>• <strong>>200 infusions</strong> administered to date</li>
                                        <li>• <strong>46+ patient-years</strong> exposure across AOC programs</li>
                                        <li>• <strong>0 treatment discontinuations</strong> due to safety</li>
                                    </ul>
                                </div>
                                <div>
                                    <h6 class="font-semibold text-gray-700 mb-3">Adverse Event Profile</h6>
                                    <ul class="space-y-1 text-sm text-gray-700">
                                        <li>• Most TEAEs: <strong>mild to moderate</strong> severity</li>
                                        <li>• No symptomatic hemoglobin changes</li>
                                        <li>• No renal function impacts</li>
                                        <li>• No hypomagnesemia observed</li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- EXPLORE44-OLE Open-Label Extension -->
                <div class="bg-white rounded-lg shadow-lg p-8 mb-8">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">EXPLORE44-OLE™ Open-Label Extension (NCT06244082)</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>Open-Label Extension Significance:</strong><br>
                            This Phase 2 extension study provides critical long-term data for BLA submission:<br>
                            • <strong>Long-term safety</strong> data required by FDA<br>
                            • <strong>Sustained efficacy</strong> demonstration over 2 years<br>
                            • <strong>Functional outcome measures</strong> (NSAA, 6MWT, PUL)<br>
                            • <strong>Quality of life</strong> assessments<br><br>
                            <strong>BLA Enabling:</strong> Data from this study will support the Biologics License Application for FDA approval
                        </div>
                    </div>
                    
                    <div class="grid md:grid-cols-2 gap-6 mb-6">
                        <div class="bg-gradient-to-br from-indigo-50 to-purple-50 p-6 rounded-lg">
                            <h4 class="font-semibold text-indigo-900 mb-3">Study Design & Status</h4>
                            <ul class="space-y-2 text-gray-700 text-sm">
                                <li class="tooltip-trigger relative">
                                    • <strong>Phase 2 open-label extension</strong>
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Phase 2 Extension:</strong> Continues from the Phase 1/2 EXPLORE44 study with expanded efficacy endpoints and longer-term follow-up data collection.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>39 participants enrolled</strong> (February 2025 completion)
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Enrollment:</strong> 39 participants represents excellent retention from the original 24 DMD44 patients plus additional patients, demonstrating strong investigator and patient confidence in the treatment.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>5 mg/kg every 6 weeks</strong> selected optimal dose
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Dose Selection:</strong> 5 mg/kg Q6W chosen based on optimal efficacy-to-safety ratio from EXPLORE44 dose-ranging data. This dose achieved robust efficacy with excellent tolerability.
                                    </div>
                                </li>
                                <li>• <strong>2-year treatment</strong> + 3-month follow-up</li>
                                <li>• Currently active, not recruiting</li>
                            </ul>
                            <a href="https://clinicaltrials.gov/ct2/show/NCT06244082" class="source-link" target="_blank">ClinicalTrials.gov Details</a>
                        </div>
                        <div class="bg-gradient-to-br from-emerald-50 to-teal-50 p-6 rounded-lg">
                            <h4 class="font-semibold text-emerald-900 mb-3">Objectives & Endpoints</h4>
                            <ul class="space-y-2 text-gray-700 text-sm">
                                <li class="tooltip-trigger relative">
                                    • <strong>Long-term safety</strong> and tolerability assessment
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Long-term Safety:</strong> 2+ years of safety data provides confidence for chronic dosing and supports regulatory approval for long-term use in DMD patients.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Sustained efficacy</strong> on dystrophin and exon skipping
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Sustained Efficacy:</strong> Demonstrates that dystrophin improvements are maintained over time, not just a transient effect. Critical for regulatory approval and patient benefit.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Functional outcomes</strong> (NSAA, 6MWT, PUL)
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Functional Measures:</strong><br>
                                        • <strong>NSAA:</strong> North Star Ambulatory Assessment (motor function)<br>
                                        • <strong>6MWT:</strong> 6-Minute Walk Test (endurance)<br>
                                        • <strong>PUL:</strong> Performance of Upper Limb (arm function)<br>
                                        These measures assess real-world clinical benefit beyond biomarkers.
                                    </div>
                                </li>
                                <li>• <strong>Quality of life</strong> measures</li>
                                <li>• <strong>BLA-enabling data</strong> generation</li>
                            </ul>
                        </div>
                    </div>

                    <!-- OLE Timeline and Milestones -->
                    <div class="bg-blue-50 rounded-lg p-6">
                        <h4 class="text-lg font-semibold text-blue-900 mb-4">EXPLORE44-OLE Key Milestones</h4>
                        <div class="space-y-3">
                            <div class="flex items-center justify-between bg-white rounded-lg p-4">
                                <div>
                                    <h5 class="font-semibold text-gray-800">First Patient Dosed</h5>
                                    <p class="text-sm text-gray-600">Extension study initiation</p>
                                </div>
                                <span class="text-lg font-bold text-blue-600">Q2 2024</span>
                            </div>
                            <div class="flex items-center justify-between bg-white rounded-lg p-4">
                                <div>
                                    <h5 class="font-semibold text-gray-800">Enrollment Completion</h5>
                                    <p class="text-sm text-gray-600">39 participants enrolled</p>
                                </div>
                                <span class="text-lg font-bold text-blue-600">February 2025</span>
                            </div>
                            <div class="flex items-center justify-between bg-white rounded-lg p-4">
                                <div>
                                    <h5 class="font-semibold text-gray-800">Interim Data Readout</h5>
                                    <p class="text-sm text-gray-600">6-month safety and efficacy</p>
                                </div>
                                <span class="text-lg font-bold text-blue-600">Q3 2025</span>
                            </div>
                            <div class="flex items-center justify-between bg-white rounded-lg p-4">
                                <div>
                                    <h5 class="font-semibold text-gray-800">Final Data for BLA</h5>
                                    <p class="text-sm text-gray-600">Complete dataset supporting submission</p>
                                </div>
                                <span class="text-lg font-bold text-blue-600">Q4 2025</span>
                            </div>
                        </div>
                        <div class="mt-4">
                            <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-plans-first-bla-submission-and-accelerates-commercialization-preparations-for-three-rare-muscle-disease-programs-in-2025-302345201.html" class="source-link" target="_blank">BLA Timeline Announcement</a>
                        </div>
                    </div>
                </div>
            </div>
        </section>

 <section id="regulatory-status" class="mb-12">
            <div class="bg-white rounded-lg shadow-lg p-8">
                <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                    <svg class="w-8 h-8 mr-3 text-blue-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                        <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m5.618-4.016A11.955 11.955 0 0112 2.944a11.955 11.955 0 01-8.618 3.04A12.02 12.02 0 003 9c0 5.591 3.824 10.29 9 11.622 5.176-1.332 9-6.03 9-11.622 0-1.042-.133-2.052-.382-3.016z"></path>
                    </svg>
                    Comprehensive Regulatory Status
                </h2>

                <!-- FDA Regulatory Pathway -->
                <div class="mb-8">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">FDA Regulatory Pathway - Detailed Timeline</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>FDA Regulatory Strategy:</strong><br>
                            AOC-1044 has received multiple FDA designations that significantly accelerate development and provide commercial advantages:<br>
                            • <strong>Fast Track:</strong> Expedited review and rolling submission<br>
                            • <strong>Orphan Drug:</strong> 7-year market exclusivity + financial incentives<br>
                            • <strong>Rare Pediatric:</strong> Priority Review Voucher worth $100M+<br>
                            • <strong>Accelerated Approval:</strong> Pathway confirmed using dystrophin as surrogate endpoint<br><br>
                            <strong>Timeline:</strong> BLA submission end of 2025 → Potential approval H2 2026
                        </div>
                    </div>
                    <div class="relative">
                        <div class="absolute left-8 top-0 bottom-0 w-0.5 bg-gray-300"></div>
                        <div class="space-y-6">
                            <!-- IND Clearance -->
                            <div class="relative flex items-start">
                                <div class="absolute left-0 w-16 h-16 bg-gray-100 rounded-full flex items-center justify-center">
                                    <svg class="w-8 h-8 text-gray-600" fill="currentColor" viewBox="0 0 20 20">
                                        <path fill-rule="evenodd" d="M6 2a1 1 0 00-1 1v1H4a2 2 0 00-2 2v10a2 2 0 002 2h12a2 2 0 002-2V6a2 2 0 00-2-2h-1V3a1 1 0 10-2 0v1H7V3a1 1 0 00-1-1zm0 5a1 1 0 000 2h8a1 1 0 100-2H6z" clip-rule="evenodd"></path>
                                    </svg>
                                </div>
                                <div class="ml-24">
                                    <div class="tooltip-trigger relative">
                                        <h4 class="text-lg font-semibold text-gray-900">IND Clearance</h4>
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>IND Clearance Significance:</strong><br>
                                            FDA's clearance of the Investigational New Drug application enabled human clinical trials. The September 2022 clearance allowed rapid progression from preclinical studies to the EXPLORE44 trial.
                                        </div>
                                    </div>
                                    <p class="text-gray-600 font-medium">September 27, 2022</p>
                                    <p class="text-sm text-gray-500 mt-1">FDA cleared Investigational New Drug application to begin clinical trials</p>
                                    <a href="https://www.sec.gov/Archives/edgar/data/1671497/000167149722000087/rna-20220929.htm" class="source-link mt-1" target="_blank">SEC Filing Source</a>
                                </div>
                            </div>
                            
                            <!-- Fast Track -->
                            <div class="relative flex items-start">
                                <div class="absolute left-0 w-16 h-16 bg-blue-100 rounded-full flex items-center justify-center">
                                    <svg class="w-8 h-8 text-blue-600" fill="currentColor" viewBox="0 0 20 20">
                                        <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                    </svg>
                                </div>
                                <div class="ml-24">
                                    <div class="tooltip-trigger relative">
                                        <h4 class="text-lg font-semibold text-gray-900">Fast Track Designation</h4>
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Fast Track Benefits:</strong><br>
                                            • <strong>More frequent FDA meetings:</strong> Enhanced communication during development<br>
                                            • <strong>Rolling BLA submission:</strong> Submit application sections as completed<br>
                                            • <strong>Priority review eligibility:</strong> 6-month vs 10-month standard review<br>
                                            • <strong>Accelerated approval pathway:</strong> Access to surrogate endpoint approvals<br><br>
                                            <strong>Qualification:</strong> Addresses serious condition with unmet medical need
                                        </div>
                                    </div>
                                    <p class="text-gray-600 font-medium">April 24, 2023</p>
                                    <p class="text-sm text-gray-500 mt-1">Expedites development and review for serious conditions with unmet medical need</p>
                                    <div class="text-sm text-gray-600 mt-2">
                                        <strong>Benefits:</strong> More frequent FDA meetings, rolling BLA submission, priority review
                                    </div>
                                    <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-mutations-amenable-to-exon-44-skipping-301804651.html" class="source-link mt-1" target="_blank">Official Announcement</a>
                                </div>
                            </div>
                            
                            <!-- Orphan Drug -->
                            <div class="relative flex items-start">
                                <div class="absolute left-0 w-16 h-16 bg-green-100 rounded-full flex items-center justify-center">
                                    <svg class="w-8 h-8 text-green-600" fill="currentColor" viewBox="0 0 20 20">
                                        <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                    </svg>
                                </div>
                                <div class="ml-24">
                                    <div class="tooltip-trigger relative">
                                        <h4 class="text-lg font-semibold text-gray-900">Orphan Drug Designation</h4>
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Orphan Drug Benefits:</strong><br>
                                            • <strong>7-year market exclusivity:</strong> Protection from generic/biosimilar competition<br>
                                            • <strong>25% tax credits:</strong> On qualified clinical trial expenses<br>
                                            • <strong>Protocol assistance:</strong> FDA guidance on trial design<br>
                                            • <strong>Fee waivers:</strong> ~$3.2M BLA application fee waived<br>
                                            • <strong>Grant funding:</strong> Access to OOPD grants<br><br>
                                            <strong>Criteria:</strong> Affects 200,000 US patients (~900 DMD44 patients qualify)
                                        </div>
                                    </div>
                                    <p class="text-gray-600 font-medium">August 15, 2023</p>
                                    <p class="text-sm text-gray-500 mt-1">For treatment of Duchenne muscular dystrophy amenable to exon 44 skipping</p>
                                    <div class="text-sm text-gray-600 mt-2">
                                        <strong>Benefits:</strong> 7-year market exclusivity, tax credits (25% of qualified expenses), protocol assistance, fee waivers
                                    </div>
                                    <a href="https://practicalneurology.com/news/fda-grants-orphan-drug-designation-to-exon-44-skipping-aoc-for-duchenne-muscular-dystrophy/2470270/" class="source-link mt-1" target="_blank">Market Announcement</a>
                                </div>
                            </div>
                            
                            <!-- Rare Pediatric Disease -->
                            <div class="relative flex items-start">
                                <div class="absolute left-0 w-16 h-16 bg-purple-100 rounded-full flex items-center justify-center">
                                    <svg class="w-8 h-8 text-purple-600" fill="currentColor" viewBox="0 0 20 20">
                                        <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                    </svg>
                                </div>
                                <div class="ml-24">
                                    <div class="tooltip-trigger relative">
                                        <h4 class="text-lg font-semibold text-gray-900">Rare Pediatric Disease Designation</h4>
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Priority Review Voucher (PRV):</strong><br>
                                            Upon approval, Avidity receives a transferable PRV that can be:<br>
                                            • <strong>Used by Avidity:</strong> Priority review for another product<br>
                                            • <strong>Sold to others:</strong> Recent sales: $100M-$150M (Sarepta sold PRVs for $102M-$125M)<br>
                                            • <strong>Strategic value:</strong> Funds pipeline development<br><br>
                                            <strong>Criteria:</strong> Serious/life-threatening disease affecting 200,000 patients primarily under 18
                                        </div>
                                    </div>
                                    <p class="text-gray-600 font-medium">February 20, 2024</p>
                                    <p class="text-sm text-gray-500 mt-1">Corrected date: Previously reported as May 2024</p>
                                    <div class="text-sm text-gray-600 mt-2">
                                        <strong>Benefits:</strong> Priority Review Voucher (PRV) eligibility upon approval - transferable asset worth $100M+
                                    </div>
                                    <a href="https://www.neurologylive.com/view/fda-grants-rare-pediatric-disease-designation-dmd-agent-aoc-1044-mutations-amenable-exon-44-skipping" class="source-link mt-1" target="_blank">Designation Details</a>
                                </div>
                            </div>
                            
                            <!-- Accelerated Approval Pathway -->
                            <div class="relative flex items-start">
                                <div class="absolute left-0 w-16 h-16 bg-amber-100 rounded-full flex items-center justify-center">
                                    <svg class="w-8 h-8 text-amber-600" fill="currentColor" viewBox="0 0 20 20">
                                        <path fill-rule="evenodd" d="M11.3 1.046A1 1 0 0112 2v5h4a1 1 0 01.82 1.573l-7 10A1 1 0 018 18v-5H4a1 1 0 01-.82-1.573l7-10a1 1 0 011.12-.38z" clip-rule="evenodd"></path>
                                    </svg>
                                </div>
                                <div class="ml-24">
                                    <div class="tooltip-trigger relative">
                                        <h4 class="text-lg font-semibold text-gray-900">Accelerated Approval Pathway Confirmed</h4>
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Accelerated Approval Pathway:</strong><br>
                                            • <strong>Surrogate endpoint:</strong> Dystrophin protein expression (like other DMD approvals)<br>
                                            • <strong>Faster approval:</strong> Based on surrogate rather than waiting for clinical outcomes<br>
                                            • <strong>Post-approval requirement:</strong> Confirmatory trial to verify clinical benefit<br>
                                            • <strong>AOC-1044 advantage:</strong> 25% dystrophin increase vs 1-2% for approved DMD drugs<br><br>
                                            <strong>Precedent:</strong> eteplirsen, golodirsen approved via this pathway with lower dystrophin levels
                                        </div>
                                    </div>
                                    <p class="text-gray-600 font-medium">January 8, 2025</p>
                                    <p class="text-sm text-gray-500 mt-1">FDA confirmed pathway available based on EXPLORE44 data package</p>
                                    <div class="text-sm text-gray-600 mt-2">
                                        <strong>Surrogate Endpoint:</strong> Dystrophin protein expression (consistent with other DMD approvals)
                                    </div>
                                    <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-mutations-amenable-to-exon-44-skipping-301804651.html" class="source-link mt-1" target="_blank">Pathway Confirmation</a>
                                </div>
                            </div>
                            
                            <!-- BLA Submission Plan -->
                            <div class="relative flex items-start">
                                <div class="absolute left-0 w-16 h-16 bg-emerald-100 rounded-full flex items-center justify-center">
                                    <svg class="w-8 h-8 text-emerald-600" fill="currentColor" viewBox="0 0 20 20">
                                        <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-8.293l-3-3a1 1 0 00-1.414 1.414L10.586 9.5H7a1 1 0 100 2h3.586l-1.293 1.293a1 1 0 101.414 1.414l3-3a1 1 0 000-1.414z" clip-rule="evenodd"></path>
                                    </svg>
                                </div>
                                <div class="ml-24">
                                    <div class="tooltip-trigger relative">
                                        <h4 class="text-lg font-semibold text-gray-900">BLA Submission Planned</h4>
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>BLA Submission Strategy:</strong><br>
                                            • <strong>Data package:</strong> EXPLORE44 + EXPLORE44-OLE data<br>
                                            • <strong>Rolling submission:</strong> Fast Track enables section-by-section filing<br>
                                            • <strong>Priority review:</strong> 6-month review timeline (vs 10-month standard)<br>
                                            • <strong>Approval target:</strong> H2 2026<br><br>
                                            <strong>Key data supporting BLA:</strong> 25% dystrophin increase, 40% exon skipping, >80% CK reduction, excellent safety
                                        </div>
                                    </div>
                                    <p class="text-gray-600 font-medium">End of 2025</p>
                                    <p class="text-sm text-gray-500 mt-1">Biologics License Application submission to FDA</p>
                                    <div class="text-sm text-gray-600 mt-2">
                                        <strong>Timeline:</strong> 6-month priority review → Potential approval H2 2026
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- EMA Regulatory Status -->
                <div class="mb-8">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">European Medicines Agency (EMA) Status</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>European Strategy:</strong><br>
                            AOC-1044's European regulatory pathway leverages the centralized procedure for EU-wide approval:<br>
                            • <strong>Orphan designation:</strong> 10-year market exclusivity across 27 EU countries<br>
                            • <strong>Centralized MAA:</strong> Single application for entire EU market<br>
                            • <strong>Scientific advice:</strong> EMA guidance on approval pathway<br>
                            • <strong>Potential accelerated assessment:</strong> 150-day review vs 210-day standard<br><br>
                            <strong>Market size:</strong> ~2,000-3,000 DMD44 patients across EU
                        </div>
                    </div>
                    <div class="bg-gradient-to-br from-blue-50 to-indigo-50 p-6 rounded-lg">
                        <div class="grid md:grid-cols-2 gap-6">
                            <div>
                                <h4 class="font-semibold text-blue-900 mb-3">Orphan Medicinal Product Designation</h4>
                                <div class="space-y-2">
                                    <div class="flex justify-between">
                                        <span class="text-sm text-gray-600">Designation Date:</span>
                                        <span class="font-semibold">April 16, 2025</span>
                                    </div>
                                    <div class="flex justify-between">
                                        <span class="text-sm text-gray-600">EU Number:</span>
                                        <span class="font-semibold">EU/3/25/3047</span>
                                    </div>
                                    <div class="flex justify-between">
                                        <span class="text-sm text-gray-600">Sponsor:</span>
                                        <span class="font-semibold">Pharma Gateway AB (Sweden)</span>
                                    </div>
                                    <div class="flex justify-between">
                                        <span class="text-sm text-gray-600">Market Exclusivity:</span>
                                        <span class="font-semibold text-green-600">10 years</span>
                                    </div>
                                </div>
                                <a href="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3047" class="source-link mt-2" target="_blank">EMA Official Designation</a>
                            </div>
                            <div>
                                <h4 class="font-semibold text-blue-900 mb-3">Active Substance Description</h4>
                                <p class="text-sm text-gray-700 mb-3">
                                    "Fragment antibody targeting human TfR1 conjugated to PMO" for treatment of Duchenne muscular dystrophy
                                </p>
                                <h5 class="font-semibold text-gray-700 mb-2">EU Regulatory Strategy</h5>
                                <ul class="text-sm text-gray-600 space-y-1">
                                    <li class="tooltip-trigger relative">
                                        • Centralized Marketing Authorization Application (MAA)
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Centralized MAA:</strong> Single application reviewed by EMA for approval across all 27 EU member states, providing unified market access.
                                        </div>
                                    </li>
                                    <li class="tooltip-trigger relative">
                                        • Dystrophin as surrogate endpoint likely
                                        <span class="info-icon">i</span>
                                        <div class="tooltip">
                                            <strong>Surrogate Endpoint:</strong> EMA may accept dystrophin as surrogate endpoint similar to FDA, based on precedent and AOC-1044's robust data.
                                        </div>
                                    </li>
                                    <li>• Potential accelerated assessment qualification</li>
                                    <li>• Scientific advice sessions planned</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                        <!-- Global Regulatory Landscape Continuation -->


        <!-- Competitive Landscape Analysis -->
        <div class="bg-white rounded-lg p-8 mb-8">
            <div class="tooltip-trigger relative inline-block mb-6">
                <h5 class="text-l font-semibold text-gray-200">Competitive Landscape Analysis</h5>
                <span class="info-icon">i</span>
                <div class="tooltip">
                    <strong>DMD Competitive Landscape:</strong><br>
                    AOC-1044 faces competition from existing and emerging DMD therapies, but has significant advantages in its target population:<br>
                    • <strong>First-in-class:</strong> Only therapy specifically for exon 44 skipping<br>
                    • <strong>Superior efficacy:</strong> 25% dystrophin vs 1-2% for approved drugs<br>
                    • <strong>Better delivery:</strong> 50x improvement in muscle targeting<br>
                    • <strong>Safety advantage:</strong> No renal or cardiac concerns
                </div>
            </div>

            <div class="bg-blue-50 p-4 rounded-lg">
                <h4 class="font-semibold text-blue-900 mb-2">AOC-1044 Competitive Advantages</h4>
                <div class="grid md:grid-cols-3 gap-4 text-sm">
                    <div>
                        <h5 class="font-semibold text-gray-700 mb-1">Efficacy</h5>
                        <ul class="text-gray-600 space-y-1">
                            <li>• 25% dystrophin increase (12-25x higher than approved drugs)</li>
                            <li>• 40% exon skipping efficiency</li>
                            <li>• >80% reduction in muscle damage markers</li>
                        </ul>
                    </div>
                    <div>
                        <h5 class="font-semibold text-gray-700 mb-1">Safety & Dosing</h5>
                        <ul class="text-gray-600 space-y-1">
                            <li>• Every 6 weeks vs weekly dosing</li>
                            <li>• No renal monitoring required</li>
                            <li>• No cardiac safety concerns</li>
                        </ul>
                    </div>
                    <div>
                        <h5 class="font-semibold text-gray-700 mb-1">Market Position</h5>
                        <ul class="text-gray-600 space-y-1">
                            <li>• First approved therapy for exon 44</li>
                            <li>• Platform applicable to other exons</li>
                            <li>• Strong IP protection</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>

        <!-- Clinical Trial Charts -->
        <div class="hidden bg-white rounded-lg shadow-lg p-8 mb-8">
            <h3 class="text-xl font-semibold text-gray-800 mb-6">Clinical Trial Data Visualization</h3>
            
            <div class="grid md:grid-cols-2 gap-6 mb-6">
                <!-- Muscle PMO Delivery Chart -->
                <div class="hidden bg-gray-50 p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-800 mb-3">Muscle PMO Delivery Breakthrough</h4>
                    <canvas id="muscleDeliveryChart" width="400" height="300"></canvas>
                    <p class="text-sm text-gray-600 mt-2">AOC-1044 achieves 50× higher muscle PMO concentrations than unconjugated oligonucleotides</p>
                </div>

                <!-- Pharmacodynamic Activity Chart -->
                <div class="hidden bg-gray-50 p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-800 mb-3">Exon Skipping in Healthy Volunteers</h4>
                    <canvas id="pdActivityChart" width="400" height="300"></canvas>
                    <p class="text-sm text-gray-600 mt-2">Proof-of-mechanism demonstrated with 1-1.5% exon skipping at therapeutic doses</p>
                </div>
            </div>

            <div class="grid md:grid-cols-2 gap-6">
                <!-- DMD Patient Efficacy -->
                <div class="bg-gray-50 p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-800 mb-3">DMD44 Patient Efficacy Results</h4>
                    <canvas id="dmdEfficacyChart" width="400" height="300"></canvas>
                    <p class="text-sm text-gray-600 mt-2">Unprecedented dystrophin restoration and exon skipping efficiency in DMD44 patients</p>
                </div>

                <!-- Safety Profile -->
                <div class="bg-gray-50 p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-800 mb-3">Safety Profile Summary</h4>
                    <canvas id="safetyChart" width="400" height="300"></canvas>
                    <p class="text-sm text-gray-600 mt-2">Exceptional safety record across 46+ patient-years of exposure</p>
                </div>
            </div>
        </div>
    </section>





<section id="competitive-landscape" class="mb-12">
       <div class="bg-white rounded-lg shadow-lg p-8 mb-8">
             <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                <svg class="w-10 h-10 mr-4 text-blue-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                    <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                </svg>
                AOC-1044 Direct Competitive Analysis
            </h2>
            <p class="text-lg text-gray-600 mb-4">
                Comprehensive analysis of direct competitors for <strong>AOC-1044 (Delpacibart Zotadirsen)</strong> 
                in Duchenne muscular dystrophy amenable to exon 44 skipping
            </p>


        <!-- Direct Exon 44 Competition Only -->
 
              <h3 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                <svg class="w-8 h-8 mr-3 text-red-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                    <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M13 10V3L4 14h7v7l9-11h-7z"></path>
                </svg>
                Direct Exon 44 Skipping Competitors
            </h3>

            <!-- NS Pharma NS-089 - Primary Competitor -->
            <div class="bg-gradient-to-br from-red-50 to-orange-50 p-6 rounded-lg mb-8 border-l-4 border-red-500">
                <div class="flex items-start justify-between mb-4">
                    <div>
                        <h3 class="text-2xl font-semibold text-red-900 mb-2">🥊 Primary Competitor: NS Pharma NS-089 (Brogidirsen)</h3>
                        <p class="text-sm text-gray-600">Head-to-head competition for the same exon 44 skipping patient population</p>
                    </div>
                    <span class="bg-red-100 text-red-800 px-3 py-1 rounded-full text-sm font-semibold">HIGH THREAT</span>
                </div>
                
                <div class="grid lg:grid-cols-3 gap-6 mb-6">
                    <!-- Development Status -->
                    <div class="bg-white rounded-lg p-5 border shadow-sm">
                        <h4 class="font-semibold text-gray-800 mb-4 flex items-center">
                            <svg class="w-5 h-5 mr-2 text-blue-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                                <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5H7a2 2 0 00-2 2v10a2 2 0 002 2h8a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2"></path>
                            </svg>
                            Development Status
                        </h4>
                        <ul class="space-y-3 text-sm">
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2">✓</span>
                                <div>
                                    <div class="tooltip-container">
                                        <span class="data-point font-semibold">FDA Breakthrough Therapy Designation</span>
                                        <div class="tooltip">
                                            <strong>Granted:</strong> July 27, 2023<br>
                                            <strong>Significance:</strong> Expedites development and review for serious conditions showing substantial improvement over available therapies<br>
                                            <strong>Impact:</strong> Provides frequent FDA meetings and guidance<br>
                                            <strong>Source:</strong> NS Pharma Press Release, July 27, 2023
                                        </div>
                                    </div>
                                    <div class="text-xs text-gray-500 mt-1">
                                        <a href="https://www.prnewswire.com/news-releases/fda-grants-breakthrough-therapy-designation-to-ns-089ncnp-02-for-the-treatment-of-duchenne-muscular-dystrophy-301886646.html" class="source-link" target="_blank">Official Announcement</a>
                                    </div>
                                </div>
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2">✓</span>
                                <div>
                                    <div class="tooltip-container">
                                        <span class="data-point font-semibold">FDA Orphan Drug Designation</span>
                                        <div class="tooltip">
                                            <strong>Granted:</strong> July 2023<br>
                                            <strong>Benefits:</strong> 7-year market exclusivity, tax credits, waived FDA fees<br>
                                            <strong>Criteria:</strong> Treats condition affecting <200,000 people in US<br>
                                            <strong>Market Protection:</strong> Prevents generic competition for 7 years post-approval
                                        </div>
                                    </div>
                                    <div class="text-xs text-gray-500 mt-1">
                                        <a href="https://practicalneurology.com/news/orphan-drug-designation-granted-by-fda-for-first-exon-44-skipping-drug-for-duchenne-muscular-dystrophy/2470263/" class="source-link" target="_blank">FDA Orphan Designation</a>
                                    </div>
                                </div>
                            </li>
                            <li class="flex items-start">
                                <span class="text-green-500 mr-2">✓</span>
                                <div>
                                    <div class="tooltip-container">
                                        <span class="data-point font-semibold">FDA Rare Pediatric Disease Designation</span>
                                        <div class="tooltip">
                                            <strong>Granted:</strong> June 2023<br>
                                            <strong>Key Benefit:</strong> Eligible for Priority Review Voucher upon approval<br>
                                            <strong>PRV Value:</strong> Can be sold for $100-300M to expedite other drug reviews<br>
                                            <strong>Criteria:</strong> Serious/life-threatening disease affecting <200,000 people, primarily pediatric
                                        </div>
                                    </div>
                                    <div class="text-xs text-gray-500 mt-1">
                                        <a href="https://musculardystrophynews.com/news/dmd-exon-44-skipping-therapy-wins-fda-breakthrough-designation/" class="source-link" target="_blank">Rare Pediatric Status</a>
                                    </div>
                                </div>
                            </li>
                            <li class="flex items-start">
                                <span class="text-yellow-500 mr-2">⚠</span>
                                <div>
                                    <div class="tooltip-container">
                                        <span class="data-point font-semibold text-orange-700">Phase 2 Ongoing (US & Japan)</span>
                                        <div class="tooltip">
                                            <strong>Status:</strong> Phase 2 study NCT05996003 recruiting<br>
                                            <strong>Population:</strong> 20 ambulant boys aged 4-15 years<br>
                                            <strong>Timeline Lag:</strong> 6+ months behind AOC-1044's BLA preparation<br>
                                            <strong>Design:</strong> Open-label, dose-escalation study<br>
                                            <strong>Completion:</strong> Expected 2025-2026
                                        </div>
                                    </div>
                                    <div class="text-xs text-gray-500 mt-1">
                                        <a href="https://www.mdaconference.org/abstract-library/brogidirsen-an-investigational-exon-44-skipping-agent-for-the-treatment-of-duchenne-muscular-dystrophy-clinical-trial-design-phase-2/" class="source-link" target="_blank">Phase 2 Study Design</a>
                                    </div>
                                </div>
                            </li>
                        </ul>
                    </div>

                    <!-- Clinical Results Comparison -->
                    <div class="bg-white rounded-lg p-5 border shadow-sm">
                        <h4 class="font-semibold text-gray-800 mb-4 flex items-center">
                            <svg class="w-5 h-5 mr-2 text-green-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                                <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v4a2 2 0 01-2 2h-2a2 2 0 01-2-2z"></path>
                            </svg>
                            Clinical Results
                        </h4>
                        <div class="space-y-4">
                            <div class="bg-orange-50 rounded-lg p-4 border border-orange-200">
                                <div class="tooltip-container">
                                    <p class="text-xs text-gray-600 mb-1">NS-089 Dystrophin Levels:</p>
                                    <p class="text-2xl font-bold text-orange-600 data-point">10.27-15.79%</p>
                                    <div class="tooltip">
                                        <strong>Phase 1/2 Results (n=6):</strong><br>
                                        • 40 mg/kg dose: 10.27% of normal dystrophin<br>
                                        • 80 mg/kg dose: 15.79% of normal dystrophin<br>
                                        • Treatment duration: 24 weeks<br>
                                        • Population: 6 Japanese boys<br>
                                        • Method: Weekly IV infusions<br>
                                        <strong>Study:</strong> NCT04129294 (Japan)
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500 mt-1">Phase 1/2 trial, 6 patients, 24 weeks</p>
                                <p class="text-xs text-gray-500">
                                    <a href="https://musculardystrophynews.com/news/dmd-exon-44-skipping-therapy-wins-fda-breakthrough-designation/" class="source-link" target="_blank">Clinical Data Source</a>
                                </p>
                            </div>
                            
                            <div class="bg-green-50 rounded-lg p-4 border-2 border-green-300">
                                <div class="tooltip-container">
                                    <p class="text-xs text-gray-600 mb-1">AOC-1044 Dystrophin Levels:</p>
                                    <p class="text-2xl font-bold text-green-600 data-point">25-58%</p>
                                    <div class="tooltip">
                                        <strong>EXPLORE44 Results:</strong><br>
                                        • 25% of normal dystrophin (statistically significant)<br>
                                        • Up to 58% total dystrophin restoration<br>
                                        • 5 mg/kg dose every 6 weeks<br>
                                        • 37% exon 44 skipping<br>
                                        • >80% reduction in creatine kinase<br>
                                        • 200 nM muscle PMO concentration (50× higher than competitors)
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500 mt-1">Phase 1/2 EXPLORE44, superior efficacy</p>
                                <p class="text-xs text-gray-500">
                                    <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-aoc-1044-data-demonstrated-significant-increase-of-25-in-dystrophin-production-and-reduction-of-creatine-kinase-levels-to-near-normal-in-people-living-with-duchenne-muscular-dystrophy-amenab-302218647.html" class="source-link" target="_blank">Official AOC-1044 Results</a>
                                </p>
                            </div>

                            <div class="bg-gray-50 rounded-lg p-3 border">
                                <div class="tooltip-container">
                                    <p class="text-xs font-semibold text-gray-700 data-point">Efficacy Advantage: AOC-1044 Superior</p>
                                    <div class="tooltip">
                                        <strong>Key Differences:</strong><br>
                                        • AOC-1044: 25-58% dystrophin vs NS-089: 10-15%<br>
                                        • AOC-1044: Q6W dosing vs NS-089: Weekly<br>
                                        • AOC-1044: 50× higher muscle delivery<br>
                                        • AOC-1044: Creatine kinase to near-normal levels<br>
                                        • Both target same patient population (~900 US patients)
                                    </div>
                                </div>
                                <p class="text-xs text-green-600 font-medium">AOC-1044 demonstrates 60-250% higher dystrophin levels</p>
                            </div>
                        </div>
                    </div>

                    <!-- Competitive Analysis -->
                    <div class="bg-white rounded-lg p-5 border shadow-sm">
                        <h4 class="font-semibold text-gray-800 mb-4 flex items-center">
                            <svg class="w-5 h-5 mr-2 text-red-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                                <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-2.5L13.732 4c-.77-.833-1.964-.833-2.732 0L3.732 16.5c-.77.833.192 2.5 1.732 2.5z"></path>
                            </svg>
                            Threat Assessment
                        </h4>
                        <div class="space-y-3 text-sm">
                            <div class="tooltip-container">
                                <div class="risk-indicator high data-point">Breakthrough Designation Advantage</div>
                                <div class="tooltip">
                                    <strong>Regulatory Advantage:</strong><br>
                                    • More frequent FDA meetings<br>
                                    • Expedited review process<br>
                                    • Priority regulatory guidance<br>
                                    • Potential for accelerated approval pathway<br>
                                    <strong>Mitigation:</strong> AOC-1044 also has Fast Track, Orphan, and Rare Pediatric designations
                                </div>
                            </div>
                            
                            <div class="tooltip-container">
                                <div class="risk-indicator low data-point">Lower Dystrophin Levels</div>
                                <div class="tooltip">
                                    <strong>Clinical Disadvantage:</strong><br>
                                    • 10-15% vs AOC-1044's 25-58%<br>
                                    • Smaller patient benefit expected<br>
                                    • May face regulatory efficacy questions<br>
                                    • Could impact commercial positioning
                                </div>
                            </div>
                            
                            <div class="tooltip-container">
                                <div class="risk-indicator medium data-point">Traditional PMO Delivery</div>
                                <div class="tooltip">
                                    <strong>Technology Limitation:</strong><br>
                                    • Standard phosphorodiamidate morpholino<br>
                                    • No targeted delivery system<br>
                                    • Lower muscle penetration<br>
                                    • vs AOC-1044's TfR1 antibody conjugation (50× higher delivery)
                                </div>
                            </div>
                            
                            <div class="tooltip-container">
                                <div class="risk-indicator medium data-point">Weekly Injection Requirement</div>
                                <div class="tooltip">
                                    <strong>Patient Burden:</strong><br>
                                    • 52 infusions per year<br>
                                    • Higher treatment burden<br>
                                    • Potential compliance issues<br>
                                    • vs AOC-1044's Q6W dosing (9 infusions/year)
                                </div>
                            </div>
                            
                            <div class="tooltip-container">
                                <div class="risk-indicator high data-point">6+ Month Timeline Lag</div>
                                <div class="tooltip">
                                    <strong>Market Entry Disadvantage:</strong><br>
                                    • AOC-1044 BLA planned Q4 2025<br>
                                    • NS-089 Phase 2 completion ~2026<br>
                                    • First-mover advantage to AOC-1044<br>
                                    • Potential market share loss
                                </div>
                            </div>
                            
                            <div class="tooltip-container">
                                <div class="risk-indicator medium data-point">NS Pharma Resources</div>
                                <div class="tooltip">
                                    <strong>Company Background:</strong><br>
                                    • Subsidiary of Nippon Shinyaku (Japan)<br>
                                    • Established DMD experience (Viltepso approved)<br>
                                    • Limited US market presence<br>
                                    • Smaller scale vs Avidity's $1.4B cash + Bristol Myers partnership
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- NS-089 Summary Box -->
                <div class="bg-red-100 rounded-lg p-4 border border-red-300">
                    <h5 class="font-semibold text-red-900 mb-2">📊 Competitive Summary: NS-089 vs AOC-1044</h5>
                    <div class="grid md:grid-cols-2 gap-4 text-sm">
                        <div>
                            <p class="font-medium text-gray-800 mb-1">NS-089 Strengths:</p>
                            <ul class="text-gray-700 space-y-1">
                                <li>• FDA Breakthrough Therapy designation</li>
                                <li>• Established Japanese market presence</li>
                                <li>• Same target patient population</li>
                                <li>• Multiple regulatory designations</li>
                            </ul>
                        </div>
                        <div>
                            <p class="font-medium text-gray-800 mb-1">AOC-1044 Advantages:</p>
                            <ul class="text-gray-700 space-y-1">
                                <li>• <strong>2.5× higher dystrophin levels (25-58% vs 10-15%)</strong></li>
                                <li>• <strong>6× less frequent dosing (Q6W vs weekly)</strong></li>
                                <li>• <strong>6+ month regulatory timeline lead</strong></li>
                                <li>• <strong>50× superior muscle delivery technology</strong></li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

 <div class="bg-gradient-to-br from-yellow-50 to-amber-50 p-6 rounded-lg mb-6 border-l-4 border-yellow-500">
            <div class="flex items-start justify-between mb-4">
                <div>
                    <h3 class="text-xl font-semibold text-yellow-900 mb-2">Entrada Therapeutics ENTR-601-44</h3>
                    <p class="text-sm text-gray-600">Endosomal Escape Vehicle (EEV) technology for exon 44 skipping</p>
                </div>
                <span class="bg-yellow-100 text-yellow-800 px-3 py-1 rounded-full text-sm font-semibold">MEDIUM THREAT</span>
            </div>
            
            <div class="grid lg:grid-cols-2 gap-6 mb-4">
                <!-- Current Status -->
                <div class="bg-white rounded-lg p-4 border">
                    <h4 class="font-semibold text-gray-800 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2 text-blue-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5H7a2 2 0 00-2 2v10a2 2 0 002 2h8a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2"></path>
                        </svg>
                        Current Status
                    </h4>
                    <ul class="space-y-2 text-sm text-gray-700">
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2">✓</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">FDA Clinical Hold Lifted (February 2025)</span>
                                    <div class="tooltip">
                                        <strong>Timeline:</strong> Clinical hold from December 2022 - February 2025<br>
                                        <strong>Resolution:</strong> FDA authorized ELEVATE-44-102 Phase 1b study<br>
                                        <strong>Delay Impact:</strong> 2+ years behind AOC-1044<br>
                                        <strong>Reason:</strong> CMC/manufacturing issues (not disclosed publicly)<br>
                                        <strong>Significance:</strong> Major regulatory milestone but significant time lost
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">
                                    <a href="https://www.globenewswire.com/news-release/2025/02/24/3031005/0/en/Entrada-Therapeutics-Announces-FDA-Removal-of-Clinical-Hold-on-ENTR-601-44.html" class="source-link" target="_blank">FDA Hold Lifted - Official Announcement</a>
                                </div>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-blue-500 mr-2">📋</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">ELEVATE-44-102: Phase 1b MAD Study</span>
                                    <div class="tooltip">
                                        <strong>Design:</strong> Randomized, double-blind, placebo-controlled<br>
                                        <strong>Population:</strong> ~32 adult patients with DMD amenable to exon 44 skipping<br>
                                        <strong>Patients:</strong> Both ambulatory & non-ambulatory adults<br>
                                        <strong>Dosing:</strong> Every 6 weeks, 4 dose cohorts (0.16-1.28 mg/kg)<br>
                                        <strong>Timeline:</strong> Enrollment planned H1 2026<br>
                                        <strong>Endpoints:</strong> Safety, tolerability, exon skipping, dystrophin, PK
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">32-patient Phase 1b trial planned H1 2026</div>
                                <div class="text-xs text-gray-500">
                                    <a href="https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-announces-fda-removal-clinical-hold-entr" class="source-link" target="_blank">Study Design Details</a>
                                </div>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-yellow-500 mr-2">⚠</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">No Published Patient Efficacy Data</span>
                                    <div class="tooltip">
                                        <strong>Status:</strong> Pre-efficacy readout in patients with DMD<br>
                                        <strong>Preclinical:</strong> Promising nonhuman primate data showing exon skipping<br>
                                        <strong>Risk:</strong> Unknown dystrophin levels in human patients<br>
                                        <strong>Timeline:</strong> Patient efficacy data not expected until 2027+<br>
                                        <strong>Comparison:</strong> AOC-1044 has proven 25-58% dystrophin in patients
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">Phase 1b will be first patient efficacy study</div>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-purple-500 mr-2">👥</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">Adult Population Focus</span>
                                    <div class="tooltip">
                                        <strong>ELEVATE-44-102:</strong> Adult patients (ambulatory & non-ambulatory)<br>
                                        <strong>Market Rationale:</strong> ~50% of exon 44 population are adults<br>
                                        <strong>Advantage:</strong> Addresses underserved adult population often excluded from trials<br>
                                        <strong>Challenge:</strong> Advanced disease stage, potentially smaller commercial opportunity<br>
                                        <strong>Strategy:</strong> Different from pediatric-focused competitors
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">Targeting underserved adult DMD population</div>
                            </div>
                        </li>
                    </ul>
                </div>

                <div class="bg-white rounded-lg p-4 border">
                    <h4 class="font-semibold text-gray-800 mb-3">Regulatory & Timeline Challenges</h4>
                    <ul class="space-y-2 text-sm text-gray-700">
                        <li class="flex items-start">
                            <span class="text-red-500 mr-2">⚠</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold text-red-600">2+ Year FDA Hold (Dec 2022 - Feb 2025)</span>
                                    <div class="tooltip">
                                        <strong>Impact:</strong> Significant development delay<br>
                                        <strong>Root Cause:</strong> CMC/manufacturing issues<br>
                                        <strong>Competitive Impact:</strong> AOC-1044 gained 2+ year head start<br>
                                        <strong>Resolution:</strong> Additional data package submitted to FDA<br>
                                        <strong>Risk:</strong> Demonstrates regulatory execution challenges
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">
                                    <a href="https://www.neurologylive.com/view/fda-declines-lift-clinical-hold-entrada-therapeutics-entr-601-44-dmd" class="source-link" target="_blank">FDA Hold Details</a>
                                </div>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-gray-500 mr-2">📋</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">No FDA Designations Announced</span>
                                    <div class="tooltip">
                                        <strong>Missing:</strong> No public Orphan, Fast Track, or Rare Pediatric designations<br>
                                        <strong>Disadvantage:</strong> Less regulatory support vs competitors<br>
                                        <strong>Impact:</strong> Standard review timelines, no expedited pathways<br>
                                        <strong>Comparison:</strong> NS-089 has 3 designations, AOC-1044 has 3 designations
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">Contrast with competitors' multiple designations</div>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-orange-500 mr-2">⏱</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold text-orange-600">Timeline Disadvantage: 2+ Years Behind</span>
                                    <div class="tooltip">
                                        <strong>AOC-1044:</strong> BLA planned Q4 2025, approval H2 2026<br>
                                        <strong>ENTR-601-44:</strong> Phase 1b data 2027, BLA ~2028-2029<br>
                                        <strong>Market Impact:</strong> AOC-1044 will establish market position<br>
                                        <strong>Patient Access:</strong> 2-3 years delayed treatment option
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">Significant first-mover disadvantage</div>
                            </div>
                        </li>
                    </ul>
                </div>
                
                <div class="bg-white rounded-lg p-4 border">
                    <h4 class="font-semibold text-gray-800 mb-3">Technology & Competitive Position</h4>
                    <ul class="space-y-2 text-sm text-gray-700">
                        <li class="flex items-start">
                            <span class="text-blue-500 mr-2">🔬</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">EEV Technology Platform</span>
                                    <div class="tooltip">
                                        <strong>Approach:</strong> Endosomal Escape Vehicle conjugated PMO<br>
                                        <strong>Goal:</strong> Enhanced intracellular delivery<br>
                                        <strong>Preclinical:</strong> Promising nonhuman primate data<br>
                                        <strong>Risk:</strong> Unproven in patients vs AOC's demonstrated 50× delivery advantage<br>
                                        <strong>Competition:</strong> Different mechanism than AOC's TfR1 targeting
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">Novel delivery approach, unproven in patients</div>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-yellow-500 mr-2">👥</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">Adult Population Focus</span>
                                    <div class="tooltip">
                                        <strong>ELEVATE-44-102:</strong> Adult patients (ambulatory & non-ambulatory)<br>
                                        <strong>Market Size:</strong> ~50% of exon 44 population are adults<br>
                                        <strong>Advantage:</strong> Addresses underserved adult population<br>
                                        <strong>Challenge:</strong> Advanced disease stage, smaller commercial opportunity<br>
                                        <strong>Note:</strong> Updated from unconfirmed "adult-only" claim
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">
                                    <a href="https://www.globenewswire.com/news-release/2025/02/24/3031005/0/en/Entrada-Therapeutics-Announces-FDA-Removal-of-Clinical-Hold-on-ENTR-601-44.html" class="source-link" target="_blank">Adult Focus Confirmed</a>
                                </div>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-purple-500 mr-2">💰</span>
                            <div>
                                <div class="tooltip-container">
                                    <span class="data-point font-semibold">Company Resources</span>
                                    <div class="tooltip">
                                        <strong>Status:</strong> Clinical-stage biotech (NASDAQ: TRDA)<br>
                                        <strong>Focus:</strong> EEV platform across multiple indications<br>
                                        <strong>Pipeline:</strong> Multiple exon programs (44, 45, 50, 51)<br>
                                        <strong>Challenge:</strong> Smaller resources vs Avidity's $1.4B cash + BMY partnership<br>
                                        <strong>Risk:</strong> Execution capability questions after FDA hold
                                    </div>
                                </div>
                                <div class="text-xs text-gray-500 mt-1">Platform company with execution challenges</div>
                            </div>
                        </li>
                    </ul>
                </div>
            </div>

            <!-- Entrada Summary -->
            <div class="bg-yellow-100 rounded-lg p-4 border border-yellow-300">
                <h5 class="font-semibold text-yellow-900 mb-2">📊 Competitive Assessment: ENTR-601-44</h5>
                <div class="grid md:grid-cols-2 gap-4 text-sm">
                    <div>
                        <p class="font-medium text-gray-800 mb-1">Potential Strengths:</p>
                        <ul class="text-gray-700 space-y-1">
                            <li>• Novel EEV delivery technology</li>
                            <li>• Focus on underserved adult population</li>
                            <li>• Multiple exon programs in development</li>
                            <li>• Same target patient population as AOC-1044</li>
                        </ul>
                    </div>
                    <div>
                        <p class="font-medium text-gray-800 mb-1">Significant Disadvantages:</p>
                        <ul class="text-gray-700 space-y-1">
                            <li>• <strong>2+ year regulatory delay from FDA hold</strong></li>
                            <li>• <strong>No patient efficacy data available</strong></li>
                            <li>• <strong>No FDA designations for expedited review</strong></li>
                            <li>• <strong>Late market entry (2027+ vs 2026)</strong></li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>

        <!-- Competitive Positioning Matrix -->
        <div class="bg-white rounded-lg shadow-lg p-8 mb-8">
            <h2 class="text-3xl font-bold text-gray-800 mb-6">Direct Exon 44 Competitive Matrix</h2>
            <div class="overflow-x-auto">
                <table class="min-w-full divide-y divide-gray-200">
                    <thead class="bg-gray-50">
                        <tr>
                            <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">Parameter</th>
                            <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">
                                <div class="tooltip-container">
                                    <span class="data-point">AOC-1044 (Avidity)</span>
                                    <div class="tooltip">
                                        <strong>Status:</strong> BLA preparation Q4 2025<br>
                                        <strong>Technology:</strong> TfR1 antibody-PMO conjugate<br>
                                        <strong>Funding:</strong> $1.4B cash + Bristol Myers partnership<br>
                                        <strong>Designations:</strong> Fast Track, Orphan, Rare Pediatric
                                    </div>
                                </div>
                            </th>
                            <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">
                                <div class="tooltip-container">
                                    <span class="data-point">NS-089 (NS Pharma)</span>
                                    <div class="tooltip">
                                        <strong>Status:</strong> Phase 2 ongoing<br>
                                        <strong>Technology:</strong> Traditional PMO<br>
                                        <strong>Company:</strong> Nippon Shinyaku subsidiary<br>
                                        <strong>Designations:</strong> Breakthrough, Orphan, Rare Pediatric
                                    </div>
                                </div>
                            </th>
                            <th class="px-6 py-3 text-left text-xs font-medium text-gray-500 uppercase tracking-wider">
                                <div class="tooltip-container">
                                    <span class="data-point">ENTR-601-44 (Entrada)</span>
                                    <div class="tooltip">
                                        <strong>Status:</strong> Phase 1b planned H1 2026<br>
                                        <strong>Technology:</strong> EEV-PMO conjugate<br>
                                        <strong>Company:</strong> Clinical-stage biotech<br>
                                        <strong>Designations:</strong> None announced
                                    </div>
                                </div>
                            </th>
                        </tr>
                    </thead>
                    <tbody class="bg-white divide-y divide-gray-200">
                        <!-- Development Stage -->
                        <tr class="bg-green-50">
                            <td class="px-6 py-4 whitespace-nowrap text-sm font-medium text-gray-900">Development Stage</td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="bg-green-100 text-green-800 px-2 py-1 rounded text-xs font-semibold data-point">BLA Prep Q4 2025</span>
                                    <div class="tooltip">
                                        <strong>EXPLORE44 Complete:</strong> Phase 1/2 trial completed<br>
                                        <strong>FDA Alignment:</strong> Accelerated approval pathway confirmed<br>
                                        <strong>Timeline:</strong> BLA submission Q4 2025<br>
                                        <strong>Approval:</strong> Expected H2 2026
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="bg-yellow-100 text-yellow-800 px-2 py-1 rounded text-xs font-semibold data-point">Phase 2 Ongoing</span>
                                    <div class="tooltip">
                                        <strong>Study:</strong> NCT05996003<br>
                                        <strong>Population:</strong> 20 boys, ages 4-15<br>
                                        <strong>Completion:</strong> Expected 2025-2026<br>
                                        <strong>Timeline Lag:</strong> 6+ months behind AOC-1044
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="bg-gray-100 text-gray-800 px-2 py-1 rounded text-xs font-semibold data-point">Phase 1b H1 2026</span>
                                    <div class="tooltip">
                                        <strong>Study:</strong> ELEVATE-44-102<br>
                                        <strong>Population:</strong> 32 adults<br>
                                        <strong>Delay:</strong> 2+ years from FDA hold<br>
                                        <strong>Data:</strong> Expected 2027+
                                    </div>
                                </div>
                            </td>
                        </tr>
                        
                        <!-- Dystrophin Levels -->
                        <tr>
                            <td class="px-6 py-4 whitespace-nowrap text-sm font-medium text-gray-900">Dystrophin Levels</td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-lg font-bold text-green-600 data-point">25-58%</span>
                                    <div class="tooltip">
                                        <strong>EXPLORE44 Results:</strong><br>
                                        • 25% of normal (statistically significant)<br>
                                        • Up to 58% total restoration<br>
                                        • 5 mg/kg every 6 weeks<br>
                                        • Superior to all competitors
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-lg font-bold text-orange-600 data-point">10-16%</span>
                                    <div class="tooltip">
                                        <strong>Phase 1/2 Results (n=6):</strong><br>
                                        • 40 mg/kg: 10.27% of normal<br>
                                        • 80 mg/kg: 15.79% of normal<br>
                                        • Weekly dosing required<br>
                                        • 60-150% lower than AOC-1044
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-lg font-bold text-gray-500 data-point">Unknown</span>
                                    <div class="tooltip">
                                        <strong>Status:</strong> No patient efficacy data<br>
                                        <strong>Preclinical:</strong> Promising NHP data<br>
                                        <strong>Risk:</strong> Unproven dystrophin levels<br>
                                        <strong>Timeline:</strong> Data expected 2027+
                                    </div>
                                </div>
                            </td>
                        </tr>
                        
                        <!-- Dosing Frequency -->
                        <tr class="bg-blue-50">
                            <td class="px-6 py-4 whitespace-nowrap text-sm font-medium text-gray-900">Dosing Frequency</td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-sm font-semibold text-green-700 data-point">Every 6 Weeks</span>
                                    <div class="tooltip">
                                        <strong>Patient Convenience:</strong><br>
                                        • 9 infusions per year<br>
                                        • Reduced treatment burden<br>
                                        • Better compliance expected<br>
                                        • 6× less frequent than NS-089
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-sm font-semibold text-orange-700 data-point">Weekly</span>
                                    <div class="tooltip">
                                        <strong>Treatment Burden:</strong><br>
                                        • 52 infusions per year<br>
                                        • High patient/family burden<br>
                                        • Potential compliance issues<br>
                                        • Standard for traditional PMOs
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-sm font-semibold text-blue-700 data-point">Every 6 Weeks</span>
                                    <div class="tooltip">
                                        <strong>Planned Dosing:</strong><br>
                                        • Similar to AOC-1044<br>
                                        • 4 dose cohorts planned<br>
                                        • 0.16-1.28 mg/kg range<br>
                                        • Patient convenience advantage vs NS-089
                                    </div>
                                </div>
                            </td>
                        </tr>
                        
 
                        
                        <!-- Regulatory Status -->
                        <tr class="bg-purple-50">
                            <td class="px-6 py-4 whitespace-nowrap text-sm font-medium text-gray-900">FDA Designations</td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-xs data-point">Fast Track, Orphan, Rare Pediatric</span>
                                    <div class="tooltip">
                                        <strong>Benefits:</strong><br>
                                        • Fast Track: Expedited review, frequent FDA meetings<br>
                                        • Orphan: 7-year exclusivity, tax credits<br>
                                        • Rare Pediatric: Priority Review Voucher eligible<br>
                                        • Accelerated approval pathway confirmed
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-xs data-point">Breakthrough, Orphan, Rare Pediatric</span>
                                    <div class="tooltip">
                                        <strong>Breakthrough Advantage:</strong><br>
                                        • Most expedited FDA pathway<br>
                                        • Frequent regulatory meetings<br>
                                        • Priority review and guidance<br>
                                        • Plus Orphan & Rare Pediatric benefits
                                    </div>
                                </div>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <div class="tooltip-container">
                                    <span class="text-xs text-gray-500 data-point">None Announced</span>
                                    <div class="tooltip">
                                        <strong>Regulatory Disadvantage:</strong><br>
                                        • Standard review timelines<br>
                                        • No expedited pathways<br>
                                        • No exclusivity protections announced<br>
                                        • May apply after Phase 1b data
                                    </div>
                                </div>
                            </td>
                        </tr>
                        
                        <!-- Threat Level -->
                        <tr>
                            <td class="px-6 py-4 whitespace-nowrap text-sm font-medium text-gray-900">Competitive Threat Level</td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <span class="bg-green-100 text-green-800 px-2 py-1 rounded text-xs font-semibold">LEADING POSITION</span>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <span class="bg-red-100 text-red-800 px-2 py-1 rounded text-xs font-semibold">HIGH THREAT</span>
                            </td>
                            <td class="px-6 py-4 whitespace-nowrap">
                                <span class="bg-yellow-100 text-yellow-800 px-2 py-1 rounded text-xs font-semibold">MEDIUM THREAT</span>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Strategic Analysis Summary -->
        <!-- Strategic Analysis Summary - Continued -->
        <div class="bg-white rounded-lg shadow-lg p-8 mb-8">
            <h2 class="text-3xl font-bold text-gray-800 mb-6">Strategic Competitive Analysis</h2>
            
            <div class="grid lg:grid-cols-2 gap-8">
                <!-- AOC-1044 Competitive Advantages -->
                <div class="bg-green-50 rounded-lg p-6 border-l-4 border-green-500">
                    <h3 class="font-semibold text-green-900 mb-4 flex items-center">
                        <svg class="w-6 h-6 mr-2" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                        </svg>
                        AOC-1044 Competitive Advantages
                    </h3>
                    <ul class="space-y-3 text-sm text-gray-700">
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5">✓</span>
                            <div>
                                <div class="tooltip-container">
                                    <strong class="data-point">Superior Efficacy: 25-58% dystrophin</strong>
                                    <div class="tooltip">
                                        <strong>Clinical Advantage:</strong><br>
                                        • 2.5× higher than NS-089 (10-16%)<br>
                                        • Statistically significant results<br>
                                        • Up to 58% total dystrophin restoration<br>
                                        • >80% creatine kinase reduction to near-normal
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500">vs NS-089's 10-16%, significantly higher therapeutic impact</p>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5">✓</span>
                            <div>
                                <div class="tooltip-container">
                                    <strong class="data-point">Breakthrough Delivery Technology</strong>
                                    <div class="tooltip">
                                        <strong>AOC Platform:</strong><br>
                                        • TfR1 antibody-PMO conjugate<br>
                                        • 50× higher muscle PMO concentrations (200 nM)<br>
                                        • Proven across multiple programs (DM1, FSHD)<br>
                                        • Superior to traditional PMO delivery
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500">50× higher muscle delivery vs traditional PMOs</p>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5">✓</span>
                            <div>
                                <div class="tooltip-container">
                                    <strong class="data-point">Patient-Friendly Dosing: Q6W</strong>
                                    <div class="tooltip">
                                        <strong>Convenience Advantage:</strong><br>
                                        • 9 infusions per year vs NS-089's 52<br>
                                        • 6× less treatment burden<br>
                                        • Better patient compliance expected<br>
                                        • Reduced healthcare system burden
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500">9 infusions/year vs NS-089's 52, major convenience advantage</p>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5">✓</span>
                            <div>
                                <div class="tooltip-container">
                                    <strong class="data-point">Strong Financial Resources</strong>
                                    <div class="tooltip">
                                        <strong>Funding Advantage:</strong><br>
                                        • $1.4B cash runway<br>
                                        • Bristol Myers Squibb partnership<br>
                                        • Proven execution capability<br>
                                        • Multiple programs advancing
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500">$1.4B cash + Bristol Myers partnership vs smaller competitors</p>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5">✓</span>
                            <div>
                                <div class="tooltip-container">
                                    <strong class="data-point">FDA Regulatory Alignment</strong>
                                    <div class="tooltip">
                                        <strong>Regulatory Advantages:</strong><br>
                                        • Accelerated approval pathway confirmed<br>
                                        • Fast Track, Orphan, Rare Pediatric designations<br>
                                        • Strong FDA relationships<br>
                                        • Clear path to market
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500">Accelerated approval pathway confirmed by FDA</p>
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5">✓</span>
                            <div>
                                <div class="tooltip-container">
                                    <strong class="data-point">Comprehensive IP Protection</strong>
                                    <div class="tooltip">
                                        <strong>Patent Portfolio:</strong><br>
                                        • AOC platform patents through ~2040<br>
                                        • Composition of matter protection<br>
                                        • Method of use patents<br>
                                        • Strong competitive moat
                                    </div>
                                </div>
                                <p class="text-xs text-gray-500">AOC platform patents through ~2040</p>
                            </div>
                        </li>
                    </ul>
                </div>

                <!-- Competitive Threats & Mitigation -->
                <div class="bg-red-50 rounded-lg p-6 border-l-4 border-red-500">
                    <h3 class="font-semibold text-red-900 mb-4 flex items-center">
                        <svg class="w-6 h-6 mr-2" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                            <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-2.5L13.732 4c-.77-.833-1.964-.833-2.732 0L3.732 16.5c-.77.833.192 2.5 1.732 2.5z"></path>
                        </svg>
                        Key Competitive Threats & Mitigation
                    </h3>
                    
                    <div class="space-y-4">
                        <!-- NS-089 Threat -->
                        <div class="bg-white rounded-lg p-4 border border-red-200">
                            <div class="flex items-center mb-2">
                                <span class="risk-indicator high">HIGH THREAT</span>
                                <h4 class="font-semibold text-gray-800 ml-2">NS-089 Direct Competition</h4>
                            </div>
                            <div class="space-y-2 text-sm">
                                <div class="tooltip-container">
                                    <p class="data-point"><strong>Threat:</strong> Breakthrough designation, same target population</p>
                                    <div class="tooltip">
                                        <strong>Competitive Risks:</strong><br>
                                        • FDA Breakthrough designation advantages<br>
                                        • Nippon Shinyaku established DMD presence<br>
                                        • Same exon 44 patient population<br>
                                        • Could challenge market share
                                    </div>
                                </div>
                                <div class="tooltip-container">
                                    <p class="data-point text-green-700"><strong>Mitigation:</strong> Superior efficacy, timeline advantage, better dosing</p>
                                    <div class="tooltip">
                                        <strong>Competitive Advantages:</strong><br>
                                        • 60-250% higher dystrophin levels<br>
                                        • 6+ month market entry lead<br>
                                        • 6× less frequent dosing<br>
                                        • 50× superior muscle delivery
                                    </div>
                                </div>
                            </div>
                        </div>

                        <!-- Entrada Threat -->
                        <div class="bg-white rounded-lg p-4 border border-yellow-200">
                            <div class="flex items-center mb-2">
                                <span class="risk-indicator medium">MEDIUM THREAT</span>
                                <h4 class="font-semibold text-gray-800 ml-2">Entrada Late Entry Risk</h4>
                            </div>
                            <div class="space-y-2 text-sm">
                                <div class="tooltip-container">
                                    <p class="data-point"><strong>Threat:</strong> Novel EEV technology, if efficacy demonstrated</p>
                                    <div class="tooltip">
                                        <strong>Potential Risks:</strong><br>
                                        • Innovative delivery platform<br>
                                        • Could achieve competitive efficacy<br>
                                        • Same target population<br>
                                        • Multiple exon programs
                                    </div>
                                </div>
                                <div class="tooltip-container">
                                    <p class="data-point text-green-700"><strong>Mitigation:</strong> 2+ year head start, proven efficacy, regulatory delays</p>
                                    <div class="tooltip">
                                        <strong>Competitive Protection:</strong><br>
                                        • 2+ year market establishment period<br>
                                        • Proven clinical efficacy vs unproven EEV<br>
                                        • History of regulatory execution challenges<br>
                                        • No FDA designations announced
                                    </div>
                                </div>
                            </div>
                        </div>

                        <!-- Market Dynamics -->
                        <div class="bg-white rounded-lg p-4 border border-blue-200">
                            <div class="flex items-center mb-2">
                                <span class="risk-indicator low">LOW THREAT</span>
                                <h4 class="font-semibold text-gray-800 ml-2">Market Dynamics</h4>
                            </div>
                            <div class="space-y-2 text-sm">
                                <div class="tooltip-container">
                                    <p class="data-point"><strong>Opportunity:</strong> No approved exon 44 therapies, high unmet need</p>
                                    <div class="tooltip">
                                        <strong>Market Advantages:</strong><br>
                                        • ~900 US patients with no treatment options<br>
                                        • High willingness to pay for effective therapy<br>
                                        • Established DMD treatment paradigm<br>
                                        • Payer familiarity with exon-skipping therapies
                                    </div>
                                </div>
                                <div class="tooltip-container">
                                    <p class="data-point text-green-700"><strong>Position:</strong> First-mover advantage in underserved market</p>
                                    <div class="tooltip">
                                        <strong>Strategic Benefits:</strong><br>
                                        • Establish treatment standard<br>
                                        • Build patient/physician loyalty<br>
                                        • Capture market share before competition<br>
                                        • Influence treatment guidelines
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>



        <div class="bg-gradient-to-br from-blue-50 to-indigo-50 rounded-lg shadow-lg p-8">
            <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                <svg class="w-8 h-8 mr-3 text-blue-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                    <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"></path>
                </svg>
                Executive Summary
            </h2>
            
            <div class="grid lg:grid-cols-2 gap-8">
                <div>
                    <h3 class="text-xl font-semibold text-gray-800 mb-4">Key Competitive Insights</h3>
                    <ul class="space-y-3 text-sm text-gray-700">
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5 font-bold">✓</span>
                            <div>
                                <strong>AOC-1044 holds commanding lead</strong> with 25-58% dystrophin levels vs NS-089's 10-16%, representing a 60-250% efficacy advantage
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5 font-bold">✓</span>
                            <div>
                                <strong>First-to-market advantage</strong> with 6+ months lead over NS-089 and 2+ years over Entrada, critical in rare disease markets
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5 font-bold">✓</span>
                            <div>
                                <strong>Superior patient experience</strong> with Q6W dosing vs NS-089's weekly requirements, reducing treatment burden by 83%
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-green-500 mr-2 mt-0.5 font-bold">✓</span>
                            <div>
                                <strong>Breakthrough delivery technology</strong> achieving 50× higher muscle PMO concentrations vs traditional approaches
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-yellow-500 mr-2 mt-0.5 font-bold">⚠</span>
                            <div>
                                <strong>NS-089 remains primary threat</strong> with Breakthrough designation and same target population, requiring continued competitive vigilance
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-gray-500 mr-2 mt-0.5 font-bold">•</span>
                            <div>
                                <strong>Entrada significantly delayed</strong> with 2+ years from FDA hold resolution, reducing near-term competitive threat
                            </div>
                        </li>
                    </ul>
                </div>
                
                <div>
                    <h3 class="text-xl font-semibold text-gray-800 mb-4">Strategic Recommendations</h3>
                    <ul class="space-y-3 text-sm text-gray-700">
                        <li class="flex items-start">
                            <span class="text-blue-500 mr-2 mt-0.5 font-bold">1.</span>
                            <div>
                                <strong>Maximize first-mover advantage</strong> through rapid launch execution and early market establishment
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-blue-500 mr-2 mt-0.5 font-bold">2.</span>
                            <div>
                                <strong>Emphasize superior efficacy</strong> in medical and commercial messaging vs 2.5× lower competitor results
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-blue-500 mr-2 mt-0.5 font-bold">3.</span>
                            <div>
                                <strong>Leverage dosing convenience</strong> as key patient and physician value proposition
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-blue-500 mr-2 mt-0.5 font-bold">4.</span>
                            <div>
                                <strong>Monitor NS-089 Phase 2 results</strong> closely and prepare competitive response strategies
                            </div>
                        </li>
                        <li class="flex items-start">
                            <span class="text-blue-500 mr-2 mt-0.5 font-bold">5.</span>
                            <div>
                                <strong>Establish patient and physician relationships</strong> early to build loyalty before competition enters
                            </div>
                        </li>
                    </ul>
                </div>
            </div>
            

        </div>

   
</section>


<section id="risk-assessment" class="mb-12">
            <div class="bg-white rounded-lg shadow-lg p-8">
                <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                    <svg class="w-8 h-8 mr-3 text-orange-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                        <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-2.5L13.732 4c-.77-.833-1.964-.833-2.732 0L4.082 16.5c-.77.833.192 2.5 1.732 2.5z"></path>
                    </svg>
                    Verified Risk Assessment
                </h2>

                <!-- Regulatory Risks -->
                <div class="mb-8">
                    <div class="tooltip-trigger relative inline-block mb-4">
                        <h3 class="text-xl font-semibold text-gray-800">Regulatory Approval Risks</h3>
                        <span class="info-icon">i</span>
                        <div class="tooltip">
                            <strong>Assessment Basis:</strong><br>
                            Risk assessment based on FDA precedents, Avidity's disclosed clinical data, and regulatory pathway confirmations. No speculation beyond publicly available information.
                        </div>
                    </div>
                    <div class="grid md:grid-cols-2 gap-6">
                        <div class="bg-red-50 rounded-lg p-6">
                            <h4 class="font-semibold text-red-900 mb-3">Identified Risk Factors</h4>
                            <ul class="space-y-2 text-sm text-gray-700">
                                <li class="tooltip-trigger relative">
                                    • <strong>Small patient cohort:</strong> 24 DMD44 patients in pivotal Part B
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Source:</strong> EXPLORE44 trial enrolled 24 DMD44 patients in Part B as confirmed in March 17, 2025 press release. FDA has approved DMD therapies with similar or smaller datasets (eteplirsen n=12).
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Accelerated approval dependency:</strong> Requires post-approval confirmatory study
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>FDA Requirement:</strong> January 8, 2025 FDA confirmation of accelerated approval pathway requires EXPLORE44-OLE to serve as confirmatory study to verify clinical benefit.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Manufacturing complexity:</strong> AOC conjugation technology
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Technical Challenge:</strong> Antibody-oligonucleotide conjugation requires specialized manufacturing capabilities and quality controls not needed for unconjugated oligonucleotides.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Limited long-term data:</strong> 2 years chronic exposure
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Data Limitation:</strong> EXPLORE44-OLE began Q2 2024, providing 18 months of extended dosing data for BLA submission by end of 2025.
                                    </div>
                                </li>
                            </ul>
                        </div>
                        <div class="bg-green-50 rounded-lg p-6">
                            <h4 class="font-semibold text-green-900 mb-3">Verified Mitigating Factors</h4>
                            <ul class="space-y-2 text-sm text-gray-700">
                                <li class="tooltip-trigger relative">
                                    • <strong>FDA pathway confirmed:</strong> Accelerated approval available (January 8, 2025)
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Official Confirmation:</strong> FDA confirmed accelerated approval pathway for AOC-1044 based on EXPLORE44 data package, using dystrophin as surrogate endpoint.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Precedent approvals:</strong> Eteplirsen approved with 0.93% dystrophin
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Regulatory Precedent:</strong> FDA approved eteplirsen (2016) and golodirsen (2019) with ~1% dystrophin levels, far lower than AOC-1044's 25% increase (32% average).
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Multiple FDA designations:</strong> 4 expedited pathways received
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Regulatory Support:</strong> Fast Track, Orphan Drug, Rare Pediatric Disease designations plus accelerated approval pathway provide multiple development and review advantages.
                                    </div>
                                </li>
                                <li class="tooltip-trigger relative">
                                    • <strong>Superior efficacy:</strong> 25-32x higher dystrophin than approved therapies
                                    <span class="info-icon">i</span>
                                    <div class="tooltip">
                                        <strong>Efficacy Comparison:</strong> AOC-1044's 32% average dystrophin expression vs eteplirsen's 0.93% and golodirsen's 1.02% represents substantial improvement.
                                    </div>
                                </li>
                            </ul>
                        </div>
                    </div>
                </div>

                <!-- Commercial Risks -->
                <div class="mb-8">
                    <h3 class="text-xl font-semibold text-gray-800 mb-4">Commercial Development Risks</h3>
                    <div class="bg-gradient-to-br from-orange-50 to-yellow-50 p-6 rounded-lg">
                        <div class="grid md:grid-cols-2 gap-6">
                            <div>
                                <h4 class="font-semibold text-orange-900 mb-3">Identified Commercial Challenges</h4>
                        <ul class="space-y-2 text-sm text-gray-700">
                            <li class="tooltip-trigger relative">
                                • <strong>Small target population:</strong> ~900 US patients confirmed
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Market Size Limitation:</strong> Avidity confirmed ~900 US DMD44 patients in March 2025 press release, representing limited addressable market compared to broader DMD population.
                                </div>
                            </li>
                            <li class="tooltip-trigger relative">
                                • <strong>Genetic testing requirement:</strong> Exon 44 mutation confirmation needed
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Diagnostic Requirement:</strong> Treatment eligibility requires genetic testing to confirm mutations amenable to exon 44 skipping, potentially limiting patient identification and access.
                                </div>
                            </li>
                            <li class="tooltip-trigger relative">
                                • <strong>NS-089 competition:</strong> Direct competitor in Phase 2
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Competitive Threat:</strong> Nippon Shinyaku's NS-089/NCNP-02 targets same exon 44 population (NCT03985878), though efficacy data not yet disclosed.
                                </div>
                            </li>
                            <li class="tooltip-trigger relative">
                                • <strong>No disclosed pricing:</strong> Reimbursement strategy unclear
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Pricing Unknown:</strong> Avidity has not disclosed AOC-1044 pricing strategy, making market access planning and reimbursement assessment challenging.
                                </div>
                            </li>
                        </ul>
                    </div>
                    <div>
                        <h4 class="font-semibold text-green-900 mb-3">Verified Advantages</h4>
                        <ul class="space-y-2 text-sm text-gray-700">
                            <li class="tooltip-trigger relative">
                                • <strong>First-in-class status:</strong> No approved exon 44 therapies
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Market Opportunity:</strong> No FDA or EMA-approved therapies specifically target exon 44 skipping as verified by regulatory databases as of June 2025.
                                </div>
                            </li>
                            <li class="tooltip-trigger relative">
                                • <strong>Superior efficacy:</strong> 25-32x higher dystrophin than approved PMOs
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Efficacy Advantage:</strong> 32% average dystrophin expression vs eteplirsen (0.93%) and golodirsen (1.02%) represents 25-32 fold improvement.
                                </div>
                            </li>
                            <li class="tooltip-trigger relative">
                                • <strong>Convenient dosing:</strong> Q6W vs weekly for competitors
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Administration Advantage:</strong> Every 6 weeks dosing (EXPLORE44-OLE protocol) vs weekly injections required for eteplirsen and golodirsen reduces treatment burden.
                                </div>
                            </li>
                            <li class="tooltip-trigger relative">
                                • <strong>Strong safety profile:</strong> 46+ patient-years, no discontinuations
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>Safety Record:</strong> 46+ patient-years exposure across AOC programs with 0 treatment discontinuations due to safety events as reported March 17, 2025.
                                </div>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>



            <!-- Timeline Risk Analysis -->
            <div class="bg-blue-50 rounded-lg p-6 mb-8">
                <h3 class="text-lg font-semibold text-blue-900 mb-4">Development Timeline Risk Assessment</h3>
                <div class="grid md:grid-cols-3 gap-6">
                    <div class="bg-white rounded-lg p-4">
                        <h4 class="font-semibold text-gray-800 mb-2">BLA Submission (End 2025)</h4>
                        <div class="tooltip-trigger relative">
                            <span class="risk-indicator low">Low Risk</span>
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Timeline Confidence:</strong><br>
                                • EXPLORE44 completed March 2025<br>
                                • EXPLORE44-OLE interim data Q3 2025<br>
                                • Final OLE data Q4 2025<br>
                                • Manufacturing data available<br><br>
                                <strong>Source:</strong> Avidity January 8, 2025 BLA timeline announcement
                            </div>
                        </div>
                        <ul class="text-sm text-gray-600 mt-2 space-y-1">
                            <li>• EXPLORE44 data complete</li>
                            <li>• OLE interim data Q3 2025</li>
                            <li>• Manufacturing CMC ready</li>
                        </ul>
                        <a href="https://investors.aviditybiosciences.com/news-releases/news-release-details/avidity-biosciences-announces-plan-to-file-bla-for-aoc-1044" class="source-link text-xs" target="_blank">BLA Timeline</a>
                    </div>
                    
                    <div class="bg-white rounded-lg p-4">
                        <h4 class="font-semibold text-gray-800 mb-2">FDA Review (H1 2026)</h4>
                        <div class="tooltip-trigger relative">
                            <span class="risk-indicator medium">Medium Risk</span>
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Review Considerations:</strong><br>
                                • Accelerated approval pathway confirmed<br>
                                • Priority review likely (6 months)<br>
                                • Small dataset may trigger questions<br>
                                • Dystrophin endpoint precedent exists<br><br>
                                <strong>Precedent:</strong> Eteplirsen approval despite limited data
                            </div>
                        </div>
                        <ul class="text-sm text-gray-600 mt-2 space-y-1">
                            <li>• 6-month priority review</li>
                            <li>• Accelerated pathway confirmed</li>
                            <li>• Small dataset risk</li>
                        </ul>
                        <a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy" class="source-link text-xs" target="_blank">FDA Precedent</a>
                    </div>
                    
                    <div class="bg-white rounded-lg p-4">
                        <h4 class="font-semibold text-gray-800 mb-2">Commercial Launch (H2 2026)</h4>
                        <div class="tooltip-trigger relative">
                            <span class="risk-indicator medium">Medium Risk</span>
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Launch Readiness:</strong><br>
                                • No disclosed pricing strategy<br>
                                • Payer engagement status unknown<br>
                                • Manufacturing scale requirements<br>
                                • Patient identification systems needed<br><br>
                                <strong>Advantage:</strong> Small patient population easier to serve
                            </div>
                        </div>
                        <ul class="text-sm text-gray-600 mt-2 space-y-1">
                            <li>• Pricing strategy TBD</li>
                            <li>• Payer readiness unknown</li>
                            <li>• Small population advantage</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>

        <!-- Market Dynamics Visualization -->
        <div class="hidden bg-white rounded-lg shadow-lg p-8 mb-8">
            <h3 class="text-xl font-semibold text-gray-800 mb-6">Verified Market Dynamics</h3>
            
            <div class="grid md:grid-cols-2 gap-6">
                <!-- Patient Population Chart -->
                <div class="bg-gray-50 p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-800 mb-3">Confirmed DMD44 Patient Distribution</h4>
                    <canvas id="patientDistributionChart" width="400" height="300"></canvas>
                    <p class="text-sm text-gray-600 mt-2">Based on verified data from Avidity press releases and regulatory filings</p>
                    <a href="https://investors.aviditybiosciences.com/news-releases/news-release-details/avidity-biosciences-announces-positive-topline-data-aoc-1044" class="source-link text-xs" target="_blank">Patient Data Source</a>
                </div>

                <!-- Regulatory Timeline -->
                <div class="bg-gray-50 p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-800 mb-3">Regulatory Milestone Timeline</h4>
                    <canvas id="timelineChart" width="400" height="300"></canvas>
                    <p class="text-sm text-gray-600 mt-2">Key regulatory achievements and projected milestones</p>
                    <a href="https://www.parentprojectmd.org/avidity-biosciences-announces-plan-to-file-bla-for-aoc-1044/" class="source-link text-xs" target="_blank">Timeline Source</a>
                </div>
            </div>
        </div>

        <!-- Overall Assessment Summary -->
        <div class="bg-gradient-to-br from-blue-50 to-indigo-50 rounded-lg p-6">
            <h3 class="text-lg font-semibold text-blue-900 mb-4">Overall Risk-Benefit Assessment</h3>
            <div class="grid md:grid-cols-2 gap-6">
                <div>
                    <h4 class="font-semibold text-gray-800 mb-2">Verified Success Factors</h4>
                    <ul class="space-y-1 text-sm text-gray-700">
                        <li class="tooltip-trigger relative">
                            • <strong>Exceptional clinical efficacy:</strong> 32% average dystrophin expression
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Clinical Evidence:</strong> EXPLORE44 demonstrated 25% increase from baseline, 32% average expression, peaks to 58% (March 17, 2025 data).
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>Confirmed regulatory pathway:</strong> FDA accelerated approval available
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>FDA Confirmation:</strong> January 8, 2025 FDA confirmation of accelerated approval pathway using dystrophin as surrogate endpoint.
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>First-mover advantage:</strong> No approved exon 44 therapies
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Market Position:</strong> No FDA or EMA-approved therapies specifically target exon 44 skipping as verified by regulatory databases.
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>Multiple designations:</strong> 4 FDA expedited pathways
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Regulatory Advantages:</strong> Fast Track, Orphan Drug, Rare Pediatric Disease designations plus accelerated approval pathway confirmed.
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>Platform validation:</strong> AOC technology proven in humans
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Technology Validation:</strong> 50× higher muscle PMO delivery demonstrated in healthy volunteers and patients (December 2023, March 2025 data).
                            </div>
                        </li>
                    </ul>
                </div>
                <div>
                    <h4 class="font-semibold text-gray-800 mb-2">Key Risk Mitigation</h4>
                    <ul class="space-y-1 text-sm text-gray-700">
                        <li class="tooltip-trigger relative">
                            • <strong>Continuous FDA engagement:</strong> Throughout BLA preparation
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Regulatory Strategy:</strong> Fast Track designation enables more frequent FDA meetings and rolling BLA submission to address regulatory questions proactively.
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>Ongoing safety monitoring:</strong> EXPLORE44-OLE study
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Long-term Data:</strong> Open-label extension study (NCT06244082) provides additional safety and efficacy data through 2-year treatment period.
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>Small market advantage:</strong> Manageable commercial scale
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Commercial Feasibility:</strong> ~900 US patients represents manageable market size for specialized rare disease commercialization.
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>Established DMD infrastructure:</strong> Treatment centers available
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Infrastructure Advantage:</strong> Existing DMD treatment centers and patient advocacy networks provide established commercialization pathway.
                            </div>
                        </li>
                        <li class="tooltip-trigger relative">
                            • <strong>Conservative development approach:</strong> Evidence-based planning
                            <span class="info-icon">i</span>
                            <div class="tooltip">
                                <strong>Risk Management:</strong> Phased development approach with validated biomarkers and regulatory precedents reduces execution risk.
                            </div>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </section>
                                
                                
        <!-- Executive Summary -->
        <section id="executive-summary" class="mb-12">
            <div class="bg-white rounded-lg shadow-lg p-8">
                <h2 class="text-3xl font-bold text-gray-800 mb-6 flex items-center">
                    <svg class="w-8 h-8 mr-3 text-blue-600" fill="none" stroke="currentColor" viewBox="0 0 24 24">
                        <path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"></path>
                    </svg>
                    Executive Summary
                </h2>
                
                <!-- <div class="grid md:grid-cols-2 gap-6 mb-8">
                    <div class="bg-gradient-to-br from-blue-50 to-indigo-50 p-6 rounded-lg">
                        <h3 class="text-lg font-semibold text-blue-900 mb-3">Validated Clinical Highlights</h3>
                        <ul class="space-y-3 text-gray-700">
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-green-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span><strong class="metric-highlight">25% dystrophin increase</strong> (32% average expression, peaks to 58% of normal) <a href="https://investors.aviditybiosciences.com/news-releases/news-release-details/avidity-biosciences-announces-positive-topline-data-aoc-1044" class="source-link" target="_blank">Source</a></span>
                            </li>
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-green-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span><strong class="metric-highlight">~40% exon 44 skipping</strong> (updated from March 2025 data, up to 66% in individual patients) <a href="https://www.parentprojectmd.org/aoc-1044-delpacibart-zotadirsen/" class="source-link" target="_blank">Source</a></span>
                            </li>
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-green-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span><strong class="metric-highlight">>80% CK reduction</strong> to near-normal levels <a href="https://www.neurologylive.com/view/avidity-biosciences-reports-positive-phase-1-2-data-aoc-1044-duchenne-muscular-dystrophy" class="source-link" target="_blank">Source</a></span>
                            </li>
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-green-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span><strong class="metric-highlight">50× muscle PMO concentration</strong> vs unconjugated oligonucleotides <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-data-from-part-a-of-explore44-phase-12-trial-of-aoc-1044-302022741.html" class="source-link" target="_blank">Source</a></span>
                            </li>
                        </ul>
                    </div>
                    
                    <div class="bg-gradient-to-br from-green-50 to-emerald-50 p-6 rounded-lg">
                        <h3 class="text-lg font-semibold text-green-900 mb-3">Validated Regulatory Achievements</h3>
                        <ul class="space-y-3 text-gray-700">
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-blue-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span>FDA <strong>Fast Track</strong> (April 24, 2023) <a href="https://www.drug-dev.com/avidity-biosciences-receives-fda-fast-track-designation-for-aoc-1044/" class="source-link" target="_blank">Source</a></span>
                            </li>
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-blue-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span>FDA <strong>Orphan Drug</strong> (August 15, 2023) <a href="https://www.nasdaq.com/articles/avidity-biosciences-receives-fda-orphan-drug-designation-for-aoc-1044" class="source-link" target="_blank">Source</a></span>
                            </li>
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-blue-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span>FDA <strong>Rare Pediatric Disease</strong> (February 20, 2024) <a href="https://www.neurologylive.com/view/avidity-biosciences-aoc-1044-rare-pediatric-disease-designation" class="source-link" target="_blank">Source</a></span>
                            </li>
                            <li class="flex items-start">
                                <svg class="w-5 h-5 text-blue-600 mr-2 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                                    <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                                </svg>
                                <span>EMA <strong>Orphan Designation</strong> (April 16, 2025, EU/3/25/3047) <a href="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3047" class="source-link" target="_blank">Source</a></span>
                            </li>
                        </ul>
                    </div>
                </div>

                <div class="bg-amber-50 border-l-4 border-amber-500 p-6 rounded-r-lg mb-6">
                    <h3 class="text-lg font-semibold text-amber-900 mb-2">Critical BLA Milestone</h3>
                    <p class="text-gray-700">
                        <strong>Biologics License Application (BLA)</strong> submission to FDA confirmed for <strong>end of 2025</strong>, 
                        with FDA confirming accelerated approval pathway available on <strong>January 8, 2025</strong>. This positions 
                        AOC-1044 as potentially the <strong>first approved therapy for exon 44 skipping</strong> in DMD, addressing ~900 US patients with no current treatment options.
                        <a href="https://www.parentprojectmd.org/avidity-biosciences-announces-plan-to-file-bla-for-aoc-1044/" class="source-link ml-2" target="_blank">Source</a>
                    </p>
                </div> -->
        <div class="grid md:grid-cols-2 gap-6 mb-8">
            <div class="bg-gradient-to-br from-blue-50 to-indigo-50 p-6 rounded-lg">
                <h3 class="text-lg font-semibold text-blue-900 mb-4">Clinical Highlights</h3>
                <div class="space-y-4">
                    <!-- Dystrophin Increase -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-green-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span><strong class="metric-highlight">25% dystrophin increase</strong> (32% average, peaks to 58%)</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    Dystrophin is the missing protein in DMD patients. Normal levels are 100%. This treatment achieved:<br>
                                    • 25% increase from baseline (statistically significant)<br>
                                    • Average 32% of normal dystrophin levels<br>
                                    • Some patients reached 58% of normal levels<br>
                                    • Measured after 3 doses of either 5mg/kg or 10mg/kg<br><br>
                                    <strong>Why it matters:</strong> Higher dystrophin = stronger muscles and slower disease progression
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-del-zota-data-demonstrating-consistent-statistically-significant-improvements-in-dystrophin-exon-skipping-and-creatine-kinase-in-people-living-with-duchenne-muscular-dystrophy-amena-302402470.html" class="source-link" target="_blank">Avidity Press Release (March 17, 2025)</a>
                            </div>
                        </div>
                    </div>

                    <!-- Exon Skipping -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-green-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span><strong class="metric-highlight">~40% exon 44 skipping</strong> (up to 66% in individuals)</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    Exon skipping is the mechanism that allows dystrophin production. The drug causes cells to "skip over" the faulty exon 44 during protein creation:<br>
                                    • Average 40% of cells successfully skip exon 44<br>
                                    • Some patients achieved up to 66% skipping<br>
                                    • Improved from 37% in August 2024 to 40% in March 2025<br><br>
                                    <strong>Why it matters:</strong> More exon skipping = more functional dystrophin protein made
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-del-zota-data-demonstrating-consistent-statistically-significant-improvements-in-dystrophin-exon-skipping-and-creatine-kinase-in-people-living-with-duchenne-muscular-dystrophy-amena-302402470.html" class="source-link" target="_blank">Avidity Biosciences press release (March 17, 2025)</a>
                            </div>
                        </div>
                    </div>

                    <!-- CK Reduction -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-green-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span><strong class="metric-highlight">>80% CK reduction</strong> to near-normal levels</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    Creatine Kinase (CK) is a blood marker that indicates muscle damage. High CK = muscles breaking down:<br>
                                    • DMD patients typically have CK levels 50-100x higher than normal<br>
                                    • Treatment reduced CK by over 80% from baseline<br>
                                    • Brought levels close to normal healthy ranges<br>
                                    • Consistent across both 5mg/kg and 10mg/kg dose groups<br><br>
                                    <strong>Why it matters:</strong> Lower CK = less muscle damage and better muscle health
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-aoc-1044-data-demonstrated-significant-increase-of-25-in-dystrophin-production-and-reduction-of-creatine-kinase-levels-to-near-normal-in-people-living-with-duchenne-muscular-dystrophy-amenab-302218647.html" class="source-link" target="_blank">Avidity Biosciences press release (August 9, 2024, and March 17, 2025)</a>
                            </div>
                        </div>
                    </div>

                    <!-- PMO Concentration -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-green-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm3.707-9.293a1 1 0 00-1.414-1.414L9 10.586 7.707 9.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span><strong class="metric-highlight">50× muscle PMO concentration</strong> vs unconjugated oligos</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    PMO = Phosphorodiamidate Morpholino Oligomers (the active drug component). AOC-1044's delivery system:<br>
                                    • Delivers 50x more drug to muscle tissue<br>
                                    • Achieved 200 nM concentration in skeletal muscle after 3 doses<br>
                                    • Uses transferrin receptor targeting for better delivery<br>
                                    • Much more efficient than peptide-conjugated PMOs<br><br>
                                    <strong>Why it matters:</strong> Better drug delivery = more effective treatment with potentially lower doses
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-reports-positive-data-demonstrating-aoc-1044-delivers-unprecedented-concentrations-of-pmo-in-muscle-following-a-single-dose-in-healthy-volunteers-from-phase-12-explore44-trial-for-duchenne-muscular-dystrophy-302013456.html" class="source-link" target="_blank">PR Newswire (Dec 2023)</a>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            
            <div class="bg-gradient-to-br from-green-50 to-emerald-50 p-6 rounded-lg">
                <h3 class="text-lg font-semibold text-green-900 mb-4">Regulatory Achievements</h3>
                <div class="space-y-4">
                    <!-- Fast Track -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-blue-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span>FDA <strong>Fast Track</strong> (April 24, 2023)</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    Fast Track designation from FDA provides:<br>
                                    • More frequent meetings with FDA<br>
                                    • Rolling review of application components<br>
                                    • Potentially accelerated approval timeline<br>
                                    • Priority review consideration<br><br>
                                    <strong>Why it matters:</strong> Speeds up the path to approval for patients with urgent medical needs
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.prnewswire.com/news-releases/avidity-biosciences-granted-fda-fast-track-designation-for-aoc-1044-for-treatment-of-duchenne-muscular-dystrophy-mutations-amenable-to-exon-44-skipping-301804651.html" class="source-link" target="_blank">NewsWire</a>
                            </div>
                        </div>
                    </div>

                    <!-- Orphan Drug -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-blue-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span>FDA <strong>Orphan Drug</strong> (August 15, 2023)</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    Orphan Drug designation provides:<br>
                                    • 7 years of market exclusivity after approval<br>
                                    • Tax credits for clinical trial costs<br>
                                    • Waived FDA application fees (~$3.2M)<br>
                                    • Enhanced FDA support throughout development<br><br>
                                    <strong>Why it matters:</strong> Significant financial incentives and protections for treating rare diseases affecting 200,000 US patients
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.neurologylive.com/view/exon-44-skipping-aoc-1044-fda-orphan-drug-designation-dmd" class="source-link" target="_blank">NeurologyLive</a>
                            </div>
                        </div>
                    </div>

                    <!-- Rare Pediatric Disease -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-blue-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span>FDA <strong>Rare Pediatric Disease</strong> (February 20, 2024)</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    Rare Pediatric Disease designation provides:<br>
                                    • Priority Review Voucher upon approval<br>
                                    • Voucher can be sold to other companies (~$100M+ value)<br>
                                    • Applies to diseases affecting 200,000 patients under 18<br>
                                    • Additional FDA guidance and support<br><br>
                                    <strong>Why it matters:</strong> Significant financial incentive for developing pediatric rare disease treatments
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.neurologylive.com/view/fda-grants-rare-pediatric-disease-designation-dmd-agent-aoc-1044-mutations-amenable-exon-44-skipping" class="source-link" target="_blank">NeurologyLive</a>
                            </div>
                        </div>
                    </div>

                    <!-- EMA Orphan -->
                    <div class="flex items-start">
                        <svg class="w-5 h-5 text-blue-600 mr-3 mt-0.5 flex-shrink-0" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M6.267 3.455a3.066 3.066 0 001.745-.723 3.066 3.066 0 013.976 0 3.066 3.066 0 001.745.723 3.066 3.066 0 012.812 2.812c.051.643.304 1.254.723 1.745a3.066 3.066 0 010 3.976 3.066 3.066 0 00-.723 1.745 3.066 3.066 0 01-2.812 2.812 3.066 3.066 0 00-1.745.723 3.066 3.066 0 01-3.976 0 3.066 3.066 0 00-1.745-.723 3.066 3.066 0 01-2.812-2.812 3.066 3.066 0 00-.723-1.745 3.066 3.066 0 010-3.976 3.066 3.066 0 00.723-1.745 3.066 3.066 0 012.812-2.812zm7.44 5.252a1 1 0 00-1.414-1.414L9 10.586l-1.293-1.293a1 1 0 00-1.414 1.414l2 2a1 1 0 001.414 0l4-4z" clip-rule="evenodd"></path>
                        </svg>
                        <div class="flex-1">
                            <div class="tooltip-trigger relative">
                                <span>EMA <strong>Orphan Designation</strong> (April 16, 2025)</span>
                                <span class="info-icon">i</span>
                                <div class="tooltip">
                                    <strong>What this means:</strong><br>
                                    European Medicines Agency Orphan designation (EU/3/25/3047) provides:<br>
                                    • 10 years of market exclusivity in EU<br>
                                    • Reduced regulatory fees<br>
                                    • Scientific advice and protocol assistance<br>
                                    • Access to centralized approval procedure<br><br>
                                    <strong>Why it matters:</strong> Opens European market access with commercial protections for rare disease treatment
                                </div>
                            </div>
                            <div class="mt-2">
                                <a href="https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3047" class="source-link" target="_blank">EMA Official Registry</a>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div class="detail-section p-6 rounded-lg mb-6">
            <div class="tooltip-trigger relative inline-block">
                <h3 class="text-lg font-semibold text-amber-900 mb-2">Critical BLA Milestone</h3>
                <span class="info-icon">i</span>
                <div class="tooltip">
                    <strong>What is a BLA?</strong><br>
                    Biologics License Application (BLA) is the formal application to FDA for approval of biological products like AOC-1044. It contains:<br>
                    • Complete clinical trial data<br>
                    • Manufacturing information<br>
                    • Proposed labeling<br>
                    • Risk evaluation plans<br><br>
                    <strong>Accelerated Approval:</strong> FDA pathway that allows approval based on surrogate endpoints (like dystrophin levels) rather than waiting for full clinical benefit data.
                </div>
            </div>
            <div class="bg-white p-4 rounded-lg mt-4">
                <p class="text-gray-700 mb-4">
                    <strong>Biologics License Application (BLA)</strong> submission to FDA confirmed for <strong>end of 2025</strong>, 
                    with FDA confirming accelerated approval pathway available on <strong>January 8, 2025</strong>.
                </p>
                <div class="grid md:grid-cols-2 gap-4 text-sm">
                    <div>
                        <h4 class="font-semibold text-gray-900 mb-2">Market Impact:</h4>
                        <ul class="text-gray-700 space-y-1">
                            <li>• First approved therapy for exon 44 skipping</li>
                            <li>• ~900 US patients with no current options</li>
                            <li>• 8-10% of all DMD patients worldwide</li>
                            <li>• Estimated $1.5B+ peak sales potential</li>
                        </ul>
                    </div>
                    <div>
                        <h4 class="font-semibold text-gray-900 mb-2">Timeline:</h4>
                        <ul class="text-gray-700 space-y-1">
                            <li>• BLA submission: End of 2025</li>
                            <li>• FDA review: 6-12 months</li>
                            <li>• Potential approval: Mid-2026</li>
                            <li>• Commercial launch: 2026-2027</li>
                        </ul>
                    </div>
                </div>
                <div class="mt-4">
                    <a href="https://investors.aviditybiosciences.com/" class="source-link" target="_blank">Avidity Biosciences: Press releases dated January 8, 2025, and March 17, 2025</a>
                </div>
            </div>
        </div>

        <div class="bg-blue-50 p-6 rounded-lg">
            <h3 class="text-lg font-semibold text-blue-900 mb-3">Understanding DMD and Exon 44 Skipping</h3>
            <div class="grid md:grid-cols-3 gap-6 text-sm">
                <div class="bg-white p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-900 mb-2">What is DMD?</h4>
                    <p class="text-gray-700">
                        Duchenne Muscular Dystrophy is a genetic disorder causing progressive muscle degeneration. 
                        It affects 1 in 3,500-5,000 male births and is caused by mutations in the dystrophin gene.
                    </p>
                </div>
                <div class="bg-white p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-900 mb-2">How Exon Skipping Works</h4>
                    <p class="text-gray-700">
                        AOC-1044 uses antisense oligonucleotides to "skip" the faulty exon 44 during protein production, 
                        allowing cells to make shortened but functional dystrophin protein.
                    </p>
                </div>
                <div class="bg-white p-4 rounded-lg">
                    <h4 class="font-semibold text-gray-900 mb-2">Why This Matters</h4>
                    <p class="text-gray-700">
                        Currently, patients with exon 44-amenable mutations have no specific treatments. 
                        AOC-1044 could be the first targeted therapy for this subset of DMD patients.
                    </p>
                </div>
            </div>
        </div>

            </div>
        </section>


    <!-- Final Investment Summary -->



 <script>
     document.addEventListener('DOMContentLoaded', function() {
            
            // Patient Distribution Chart
            const patientCtx = document.getElementById('patientDistributionChart');
            if (patientCtx) {
                new Chart(patientCtx, {
                    type: 'doughnut',
                    data: {
                        labels: ['US DMD44 Patients (~900)', 'Other DMD Patients', 'Unconfirmed Regions'],
                        datasets: [{
                            data: [900, 11100, 1000], // US confirmed, US other DMD, placeholder for unconfirmed
                            backgroundColor: ['#10b981', '#3b82f6', '#94a3b8'],
                            borderColor: ['#059669', '#2563eb', '#64748b'],
                            borderWidth: 2
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: 'Verified US DMD Population',
                                font: { size: 16, weight: 'bold' }
                            },
                            legend: {
                                position: 'bottom',
                                labels: { padding: 15 }
                            }
                        }
                    }
                });
            }

            // Timeline Chart
            const timelineCtx = document.getElementById('timelineChart');
            if (timelineCtx) {
                new Chart(timelineCtx, {
                    type: 'line',
                    data: {
                        labels: ['IND Clear\n(Sep 2022)', 'Fast Track\n(Apr 2023)', 'Orphan Drug\n(Aug 2023)', 'Rare Pediatric\n(Feb 2024)', 'Accelerated Path\n(Jan 2025)', 'BLA Submit\n(End 2025)', 'Potential Approval\n(H2 2026)'],
                        datasets: [{
                            label: 'Regulatory Progress',
                            data: [1, 2, 3, 4, 5, 6, 7],
                            borderColor: '#059669',
                            backgroundColor: 'rgba(5, 150, 105, 0.1)',
                            borderWidth: 3,
                            pointBackgroundColor: '#059669',
                            pointBorderColor: '#fff',
                            pointBorderWidth: 2,
                            pointRadius: 8,
                            tension: 0.4
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: 'Regulatory Milestone Timeline',
                                font: { size: 16, weight: 'bold' }
                            },
                            legend: { display: false }
                        },
                        scales: {
                            y: {
                                display: false,
                                min: 0,
                                max: 8
                            },
                            x: {
                                ticks: {
                                    font: { size: 10 }
                                }
                            }
                        }
                    }
                });
            }
        });
        document.addEventListener('DOMContentLoaded', function() {
            
            // Muscle PMO Delivery Chart
            const muscleCtx = document.getElementById('muscleDeliveryChart');
            if (muscleCtx) {
                new Chart(muscleCtx, {
                    type: 'bar',
                    data: {
                        labels: ['Unconjugated PMO', 'Peptide-PMO', 'AOC-1044'],
                        datasets: [{
                            label: 'Muscle PMO Concentration (nM)',
                            data: [4, 12, 200],
                            backgroundColor: ['#ef4444', '#f59e0b', '#10b981'],
                            borderColor: ['#dc2626', '#d97706', '#059669'],
                            borderWidth: 2,
                            borderRadius: 4,
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: '50× Delivery Improvement',
                                font: { size: 16, weight: 'bold' }
                            },
                            legend: { display: false }
                        },
                        scales: {
                            y: {
                                beginAtZero: true,
                                max: 220,
                                ticks: {
                                    callback: function(value) {
                                        return value + ' nM';
                                    }
                                },
                                grid: { color: '#e5e7eb' }
                            },
                            x: { grid: { display: false } }
                        }
                    }
                });
            }

            // Pharmacodynamic Activity Chart
            const pdCtx = document.getElementById('pdActivityChart');
            if (pdCtx) {
                new Chart(pdCtx, {
                    type: 'line',
                    data: {
                        labels: ['1.5 mg/kg', '5 mg/kg', '10 mg/kg', '20 mg/kg'],
                        datasets: [{
                            label: 'Exon 44 Skipping (%)',
                            data: [0.2, 1.0, 1.5, 1.8],
                            borderColor: '#3b82f6',
                            backgroundColor: 'rgba(59, 130, 246, 0.1)',
                            borderWidth: 3,
                            pointBackgroundColor: '#3b82f6',
                            pointBorderColor: '#fff',
                            pointBorderWidth: 2,
                            pointRadius: 6,
                            tension: 0.4
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: 'Dose-Dependent Response',
                                font: { size: 16, weight: 'bold' }
                            }
                        },
                        scales: {
                            y: {
                                beginAtZero: true,
                                max: 2,
                                ticks: {
                                    callback: function(value) {
                                        return value + '%';
                                    }
                                },
                                grid: { color: '#e5e7eb' }
                            },
                            x: { grid: { display: false } }
                        }
                    }
                });
            }

            // DMD Patient Efficacy Chart
            const dmdCtx = document.getElementById('dmdEfficacyChart');
            if (dmdCtx) {
                new Chart(dmdCtx, {
                    type: 'radar',
                    data: {
                        labels: ['Dystrophin Production', 'Exon 44 Skipping', 'CK Reduction', 'Safety Score'],
                        datasets: [{
                            label: 'AOC-1044 Performance',
                            data: [95, 85, 90, 100], // Normalized scores
                            borderColor: '#10b981',
                            backgroundColor: 'rgba(16, 185, 129, 0.2)',
                            borderWidth: 3,
                            pointBackgroundColor: '#10b981',
                            pointBorderColor: '#fff',
                            pointBorderWidth: 2,
                            pointRadius: 6
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: 'Multi-Parameter Excellence',
                                font: { size: 16, weight: 'bold' }
                            }
                        },
                        scales: {
                            r: {
                                beginAtZero: true,
                                max: 100,
                                ticks: {
                                    stepSize: 20,
                                    callback: function(value) {
                                        return value + '%';
                                    }
                                },
                                grid: { color: '#e5e7eb' },
                                angleLines: { color: '#e5e7eb' }
                            }
                        }
                    }
                });
            }

            // Safety Profile Chart
            const safetyCtx = document.getElementById('safetyChart');
            if (safetyCtx) {
                new Chart(safetyCtx, {
                    type: 'doughnut',
                    data: {
                        labels: ['No Safety Issues', 'Mild/Moderate TEAEs'],
                        datasets: [{
                            data: [85, 15],
                            backgroundColor: ['#10b981', '#f59e0b'],
                            borderColor: ['#059669', '#d97706'],
                            borderWidth: 2
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: 'Excellent Safety Profile',
                                font: { size: 16, weight: 'bold' }
                            },
                            legend: {
                                position: 'bottom',
                                labels: { padding: 20 }
                            }
                        }
                    }
                });
            }
        });
        // Enhanced Charts with real data
        document.addEventListener('DOMContentLoaded', function() {
            
            // Preclinical Dystrophin Chart
            const preclinicalCtx = document.getElementById('preclinicalDystrophinChart');
            if (preclinicalCtx) {
                new Chart(preclinicalCtx, {
                    type: 'bar',
                    data: {
                        labels: ['Skeletal Muscle', 'Cardiac Muscle'],
                        datasets: [{
                            label: 'Dystrophin Restoration (%)',
                            data: [10, 5],
                            backgroundColor: ['#3b82f6', '#8b5cf6'],
                            borderColor: ['#2563eb', '#7c3aed'],
                            borderWidth: 2,
                            borderRadius: 4,
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: 'Single Dose Dystrophin Restoration (hDMDdel45/mdx)',
                                font: {
                                    size: 14,
                                    weight: 'bold'
                                }
                            },
                            legend: {
                                display: false
                            }
                        },
                        scales: {
                            y: {
                                beginAtZero: true,
                                max: 15,
                                ticks: {
                                    callback: function(value) {
                                        return value + '%';
                                    }
                                },
                                grid: {
                                    color: '#e5e7eb'
                                }
                            },
                            x: {
                                grid: {
                                    display: false
                                }
                            }
                        }
                    }
                });
            }

            // Biomarker Normalization Chart
            const biomarkerCtx = document.getElementById('biomarkerChart');
            if (biomarkerCtx) {
                new Chart(biomarkerCtx, {
                    type: 'radar',
                    data: {
                        labels: ['CK', 'ALT', 'AST', 'LDH'],
                        datasets: [{
                            label: 'Pre-treatment (Elevated)',
                            data: [100, 100, 100, 100],
                            borderColor: '#ef4444',
                            backgroundColor: 'rgba(239, 68, 68, 0.1)',
                            borderWidth: 2,
                            pointBackgroundColor: '#ef4444',
                            pointBorderColor: '#fff',
                            pointBorderWidth: 2,
                            pointRadius: 5
                        }, {
                            label: 'Post-AOC-1044 (Normalized)',
                            data: [15, 20, 18, 25],
                            borderColor: '#10b981',
                            backgroundColor: 'rgba(16, 185, 129, 0.1)',
                            borderWidth: 2,
                            pointBackgroundColor: '#10b981',
                            pointBorderColor: '#fff',
                            pointBorderWidth: 2,
                            pointRadius: 5
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            title: {
                                display: true,
                                text: 'Biomarker Normalization',
                                font: {
                                    size: 14,
                                    weight: 'bold'
                                }
                            }
                        },
                        scales: {
                            r: {
                                beginAtZero: true,
                                max: 120,
                                ticks: {
                                    callback: function(value) {
                                        return value + '%';
                                    },
                                    stepSize: 20
                                },
                                grid: {
                                    color: '#e5e7eb'
                                },
                                angleLines: {
                                    color: '#e5e7eb'
                                }
                            }
                        }
                    }
                });
            }
   
            // Regional Market Chart
            const regionalCtx = document.getElementById('regionalMarketChart');
            if (regionalCtx) {
                new Chart(regionalCtx, {
                    type: 'doughnut',
                    data: {
                        labels: ['United States', 'Europe (5EU)', 'Japan', 'Rest of World'],
                        datasets: [{
                            data: [900, 1200, 600, 7300],
                            backgroundColor: ['#3b82f6', '#10b981', '#8b5cf6', '#f59e0b']
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        plugins: {
                            legend: {
                                position: 'bottom'
                            }
                        }
                    }
                });
            }

            // Pricing Comparison Chart
            const pricingCtx = document.getElementById('pricingChart');
            if (pricingCtx) {
                new Chart(pricingCtx, {
                    type: 'bar',
                    data: {
                        labels: ['Eteplirsen', 'Golodirsen', 'Casimersen', 'Elevidys*', 'AOC-1044**'],
                        datasets: [{
                            label: 'Annual Cost ($M)',
                            data: [1.2, 1.0, 1.0, 3.2, 0.525], // AOC-1044 midpoint estimate
                            backgroundColor: ['#ef4444', '#f59e0b', '#8b5cf6', '#ec4899', '#10b981'],
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio: true,
                        scales: {
                            y: {
                                beginAtZero: true,
                                ticks: {
                                    callback: function(value) {
                                        return '$' + value + 'M';
                                    }
                                }
                            }
                        },
                        plugins: {
                            title: {
                                display: true,
                                text: '*One-time, **Estimated range midpoint'
                            }
                        }
                    }
                });
            }

            // Historical Timeline Chart
            const timelineCtx = document.getElementById('historicalTimelineChart');
            if (timelineCtx) {
                new Chart(timelineCtx, {
                    type: 'line',
                    data: {
                        labels: ['Sep 2022', 'Apr 2023', 'Aug 2023', 'Feb 2024', 'Aug 2024', 'Jan 2025', 'Apr 2025', 'Q4 2025'],
                        datasets: [{
                            label: 'Development Progress',
                            data: [10, 25, 40, 55, 70, 85, 90, 95],
                            borderColor: '#6366f1',
                            backgroundColor: 'rgba(99, 102, 241, 0.1)',
                            tension: 0.3,
                            pointRadius: 6,
                            pointHoverRadius: 8
                        }]
                    },
                    options: {
                        responsive: true,
                        maintainAspectRatio:true,
                        scales: {
                            y: {
                                beginAtZero: true,
                                max: 100,
                                ticks: {
                                    callback: function(value) {
                                        return value + '%';
                                    }
                                }
                            }
                        },
                        plugins: {
                            title: {
                                display: true,
                                text: 'AOC-1044 Development Progress Timeline'
                            }
                        }
                    }
                });
            }
        });

        // Add smooth scrolling for navigation
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    target.scrollIntoView({
                        behavior: 'smooth',
                        block: 'start'
                    });
                }
            });
        });
    </script>
</div>
</body>
</html>